ClinicalTrials.gg
CompletedNCT02443155Updated Apr 9, 2021Results posted

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

A Phase 2 interventional study of NNC0114-0006 and liraglutide in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 108 sites in 18 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2021-04-09.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
308
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.

Enrollment
3rd of 32
308 · median 38
Started
2015
with 5 others
Phase 2
10 of 32
1 open now
Registered
19th of 32
by date
Lead sponsor
5 of 32
Novo Nordisk A/S

Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is one of 6 that started in 2015, is one of 10 in phase 2, and was the 19th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing liraglutide in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 308 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
  • T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks prior to screening - Male or female, aged 18-45 (both inclusive) at the time of signing the informed consent form
  • Non-fasting peak C-peptide higher or equal to 0.2 nmol/l at visit 2
  • (body mass index) higher or equal to 18.5 kg/m\^2
  • Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening
  • Insulin dependence unless in temporary spontaneous remission (honeymoon period)

Exclusion criteria

Exclusion Criteria:

  • Daily insulin usage above 1 U/kg per day at screening or use of continuous subcutaneous insulin infusion (CSII)
  • History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections (e.g., bronchiectasis and chronic osteomyelitis)
  • History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy
  • Vaccination within 4 weeks before randomisation, Visit 3 (V3)
  • Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening (V1)
  • History of pancreatitis (acute or chronic)
  • Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)
  • Any past or current diagnosis of malignant neoplasms
  • Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, antibodies not considered clinical important (e.g. thyroid antibodies without any thyroid disease), and vitiligo
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    NNC0114-0006 + Liraglutide

    Drug: NNC0114-0006 · Drug: liraglutide

  • Experimental
    NNC0114-0006 + Placebo

    Drug: NNC0114-0006 · Drug: placebo

  • Active comparator
    Liraglutide + Placebo

    Drug: liraglutide · Drug: placebo

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment

  • Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment

  • Drugplacebo

    Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment

07

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline

    Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).

    Time frame: 0 - 4 hours post-dose on week 0 and week 54

Secondary outcomes

  1. AUC0-2h of C-peptide at Week 54 Relative to Baseline

    Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.

    Time frame: 0-2 hours post-dose on week 0 and week 54

  2. Cmax of C-peptide at Week 54 Relative to Baseline

    Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).

    Time frame: 0-4 hours post-dose on week 0 and week 54

  3. AUC0-4h of Glucose at Week 54 Relative to Baseline

    Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).

    Time frame: 0 - 4 hours post-dose on week 0 and week 54

  4. AUC0-2h of Glucose at Week 54 Relative to Baseline

    Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose is measured as 'mmol\*h/L'.

    Time frame: 0-2 hours post-dose on week 0 and week 54

  5. Cmax of Glucose at Week 54 Relative to Baseline

    Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.

    Time frame: 0-4 hours post-dose on week 0 and week 54

  6. Number of Treatment Emergent Adverse Events

    An adverse event was any untoward medical occurrence in a participants administered a product, and which did not necessarily have a causal relationship with this treatment. An adverse event was defined as treatment emergent if the onset of the adverse event occurs on or after the first day of trial product administration. Number of treatment emergent adverse events from first dose of trial product to week 54 and week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

    Time frame: Week 0-54; Week 54-80

  7. Number of Treatment Emergent Hyperglycaemic Episodes

    Hyperglycaemic episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

    Time frame: Week 0-54; Week 54-80

  8. Number of Treatment Emergent Episodes of Diabetic Ketoacidosis

    Diabetic ketoacidosis episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

    Time frame: Weeks 0-54; Weeks 54-80

  9. Number of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion

    Injection/infusion site reactions episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of participants experiencing treatment emergent episodes of injection/infusion site reactions episodes from first dose of trial product to week 54 (treatment period) is presented.

    Time frame: Week 0-54

  10. Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA)

    Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 1 day after the date of last contact. Number of treatment-emergent hypoglycaemic episodes according to American Diabetes Association (ADA) classification from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results presented hypoglycaemia episodes were recorded as per ADA definition: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Pseudo-hypoglycaemia.

    Time frame: Weeks 0-54; Weeks 54-80

  11. Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk Definitions

    Hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Severe or BG-confirmed: An episode that is severe according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.

    Time frame: Weeks 0-54; Weeks 54-80

  12. Change in Body Weight (kg)

    Change in body weight is measured at week 54 and week 80 respective to baseline. Body weight was measured in unit 'Kg'.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  13. Diabetes Retinopathy

    Number of participants evaluated for diabetic retinopathy at baseline (Day -28 to -14), week 54 and week 80 are presented as 'yes', 'no' or 'unknown'.

    Time frame: Baseline, week 54 and week 80

  14. Estimated Glomerular Filtration Rate (eGFR)- Ratio to Baseline

    The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Change in eGFR (measured in milliliters per minute per 1.73 square meters) from baseline (week 0) at week 54 and week 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  15. Change in Haematology: Erythrocytes

    Change in erythrocytes (measured in 10\^12 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  16. Change in Haematology: Haematocrit

    Change in haematocrit (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  17. Change in Haematology: Haemoglobin

    Change in haemoglobin (measured in millimoles per liter 'mmol/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  18. Change in Haematology: Leukocytes

    Change in leukocytes (measured in 10\^9 cells/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  19. Change in Haematology: Mean Corpuscular Hemoglobin

    Change in mean Corpuscular hemoglobin (measured in femtomole 'fmol') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  20. Change in Haematology: Mean Corpuscular Hemoglobin Concentration

    Change in mean corpuscular hemoglobin concentration (MCHC) (measured in gram per liter 'g/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  21. Change in Haematology: Mean Corpuscular Volume

    Change in Mean Corpuscular volume (measured in femtoliter 'fL') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  22. Change in Haematology: Thrombocytes

    Change in thrombocytes (measured in 10\^9 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  23. Change in Haematology: Eosinophil

    Change in eosinophil (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  24. Change in Haematology: Neutrophils

    Change in neutrophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  25. Change in Haematology: Basophils

    Change in basophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  26. Change in Haematology: Lymphocytes

    Change in lymphocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  27. Change in Haematology: Monocytes

    Change in monocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  28. Change in Biochemistry: Alanine Aminotransferase (ALAT)

    Change in ALAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  29. Change in Biochemistry: Albumin

    Change in albumin (measured in gram per deciliter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  30. Change in Biochemistry: Amylase

    Change in amylase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  31. Change in Biochemistry: Alkaline Phosphatase (ALP)

    Change in ALP (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  32. Change in Biochemistry: Aspartate Aminotransferase (ASAT)

    Change in ASAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  33. Change in Biochemistry: Total Bilirubin

    Change in Total bilirubin (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  34. Change in Biochemistry: Calcium Corrected

    Change in calcium corrected (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  35. Change in Biochemistry: Chloride

    Change in chloride (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  36. Change in Biochemistry: Creatine Kinase

    Change in creatine kinase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  37. Change in Biochemistry: Creatinine

    Change in creatinine (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  38. Change in Biochemistry: Gamma-glutamyl Transferase (GGT)

    Change in GGT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  39. Change in Biochemistry: C-reactive Protein Serum

    Change in C-reactive protein serum (measured in milligrams per liter \[mg/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  40. Change in Biochemistry: Lactate Dehydrogenase

    Change in Lactate Dehydrogenase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  41. Change in Biochemistry: Lipase

    Change in lipase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  42. Change in Biochemistry: Magnesium

    Change in magnesium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  43. Change in Biochemistry: Phosphate

    Change in phosphate (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  44. Change in Biochemistry: Potassium

    Change in potassium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  45. Change in Biochemistry: Sodium

    Change in sodium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  46. Change in Biochemistry: Total Protein

    Change in total protein (measured in gram per liter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  47. Change in Biochemistry: Blood Urea Nitrogen Serum

    Change in blood urea nitrogen serum (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  48. Change in Biochemistry: Uric Acid

    Change in Uric Acid (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  49. Change in International Normalised Ratio (INR)

    Change in INR (measured in ratio\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  50. Change in D-Dimer

    Change in D-Dimer (measured in mg/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  51. Change in Lipids: Total Cholesterol (Ratio to Baseline)

    Change in total cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  52. Change in Lipids: Free Fatty Acids (Ratio to Baseline)

    Change in total free fatty acids (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  53. Change in Lipids: HDL Cholesterol (Ratio to Baseline)

    Change in HDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  54. Change in Lipids: LDL Cholesterol (Ratio to Baseline)

    Change in LDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  55. Change in Lipids: Triglycerides (TG) (Ratio to Baseline)

    Change in Triglycerides (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  56. Change in Total Immunoglobulin E (IgE)

    Change in IgE (measured in kilo international units per liter \[kIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  57. Change in Urinalysis: Urine Dipsticks

    Urinalysis was performed by urine dipsticks for protein, glucose, erythrocytes, ketones leukocytes, nitrite, pH and specific gravity and categorised as normal, abnormal not clinically significant (NCS) and abnormal clinially significant (CS). Number of participants in each category at baseline (week 0), week 54 and 80 are presented.

    Time frame: Week 0, week 54 and week 80

  58. Change in Cytokines: Interleukin (IL)-6

    IL-6 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

    Time frame: Week 0, week 54 and week 80

  59. Change in Cytokines- Interleukin (IL)-10

    IL-10 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

    Time frame: Week 0, week 54 and week 80

  60. Change in Cytokines: Interleukin (IL)-17

    IL-17 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

    Time frame: Week 0, week 54 and week 80

  61. Change in Cytokines: Interferon (IFN) Gamma

    IFN gamma levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

    Time frame: Week 0, week 54 and week 80

  62. Change in Cytokines: TNF-alpha

    TNF-alpha levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

    Time frame: Week 0, week 54 and week 80

  63. Change in Hormone Level: Thyroid Stimulating Hormone (TSH)

    Change in TSH (measured in milli international units per liter \[mIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  64. Change in Hormone Level: Calcitonin

    Change in Calcitonin (measured in nanogram per liter \[ng/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  65. Change in Systolic and Diastolic Blood Pressure

    Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are evaluated from baseline (week 0) to weeks 54 and 80.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  66. Change in Pulse

    Change in pulse is evaluated from baseline (week 0) to weeks 54 and 80

    Time frame: (Week 0, week 54) and (week 0, week 80)

  67. Change in Body Temperature

    Change in body temperature is evaluated from baseline (week 0) to weeks 54 and 80.

    Time frame: Week 0, week 54) and (week 0, week 80)

  68. Change in Respiratory Rate

    Change in respiratory rate is evaluated from baseline (week 0) to weeks 54 and 80.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  69. Change in Electrocardiogram (ECG)

    The ECG was assessed by the investigator at baseline (week 0), week 54 and week 80 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline, week 54 and week 80 are presented.

    Time frame: Week 0, week 54 and week 80

  70. Change in Eye-examination

    Dilated fundoscopy or fundus photography was performed by the investigator at week 0, week 54 and week 80. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week 0, week 54 and week 80 are presented.

    Time frame: Week 0, week 54 and week 80

  71. Change in Physical Examination

    Physical examination parameters are categorised as general appearance; head, ears, eyes, nose, throat, neck; respiratory system;cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; skin; lymph node palpation and thyroid gland. Investigator assessed the participants with normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) findings at week 0, week 54 and week 80 are presented.

    Time frame: Week 0, week 54 and week 80

  72. Occurrence of Anti-NNC0114-0006 Antibodies

    This outcome measure was applicable for NNC0114-0006 + Liraglutide treatment arm and NNC0114-0006 treatment arm. Participants was assessed for anti-NNC0114-0006 antibodies. Participant who reported anti-NNC0114-0006 antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-NNC0114-0006 antibodies at week 54 and week 80 are presented.

    Time frame: Week 0, week 54 and week 80

  73. Occurrence of Anti-liraglutide Antibodies

    This outcome measure is applicable for NNC0114-0006 + Liraglutide treatment arm and Liraglutide treatment arm. Participants was assessed for anti-liraglutide antibodies. Participant who reported anti-liraglutide antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-liraglutide antibodies at week 54 and week 80 are presented.

    Time frame: Week 0, week 54 and week 80

  74. Change in Insulin Dose

    The total daily insulin dose was derived as the average of the doses reported on the three days prior to the visit. Change in daily total insulin dose from baseline (week 0) after 54 weeks of treatment and week 80 are presented.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  75. Change in Number of Insulin Injections

    The number of insulin injections was derived as the average of the reported number on the three days prior to the visit. The change in number of insulin injections per day (count) from baseline (week 0) after 54 weeks of treatment and week 80 are presented.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  76. Number of Weeks Off Bolus Insulin

    The number of weeks off bolus insulin after 54 weeks of treatment and week 80 are presented.

    Time frame: (Week 0 to week 54) and (week 0 to week 80)

  77. Change in HbA1c

    Change in glycosylated haemoglobin (HbA1c) is evaluated from baseline (week 0) to weeks 54 and 80.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  78. Change in Fasting Plasma Glucose

    Change in fasting plasma glucose is evaluated from baseline (week 0) to weeks 54 and 80.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  79. Change in Fasting C-peptide- Ratio to Baseline

    Change in fasting C-peptide (measured in nanomole per liter \[nmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  80. Change in Fasting Glucagon- Ratio to Baseline

    Change in fasting glucagon (measured in picogram per milliliter \[pg/mL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  81. 7-point SMPG Profiles

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. 7-point SMPG profile values are presented for week 54 and week 80.

    Time frame: Week 54 and Week 80

  82. Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment: Breakfast, Lunch, Dinner

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point SMPG postprandial glucose /prandial increment (breakfast, lunch and dinner) value are presented.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  83. Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment (Average Over the Three Meals)

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point self-measured plasma glucose (SMPG) postprandial glucose /prandial increment (average over the three meals) value is presented.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  84. Change in Mean of 7-point Profiles

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in mean of 7-point profiles value is presented.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  85. Before Breakfast 7- Points Self Measured Plasma Glucose (SMPG)

    Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Before breakfast 7-point self-measured plasma glucose (SMPG) profile values are presented at week 54 and week 80.

    Time frame: Week 54 and week 80

  86. Area Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006)

    AUCtau, NNC0114-0006 was derived as the area under the concentration-time curve using the linear trapezoidal technique based on observed values and actual measurement times between 0 and 6 weeks (after the last dose). This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Pre-dose and 1 hour post-dose during week 48 to week 54

  87. Terminal Half-life (t½) After Last Dose of NNC0114-0006

    Terminal half life was calculated as log(2)/λz. The terminal rate constant λz was determined through linear regression with the logarithm to concentration as the response variable and actual measurement time as the explanatory variable. Valid observations from the terminal part of the curve, which is approximately linear, were used for the determination. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80

  88. Apparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006)

    The apparent volume of distribution of NNC0114-0006 at steady-state was calculated as mean residence time of (MRT) of NNC0114-0006 multiplied by clearance of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80

  89. Clearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006)

    Clearance of NNC0114-0006 at steady state was calculated as dose/AUCtau, NNC0114-0006. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Pre-dose and 1 hour post-dose during week 48 to week 54

  90. Mean Residence Time of NNC0114-0006 (MRT, NNC0114-0006)

    This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms. Mean residence time of NNC0114-0006 is presented.

    Time frame: Pre-dose and 1 hour post-dose during week 48 to week 80

  91. Accumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006)

    Accumulation ratio of NNC114-0006 was defined as AUC48-54 weeks/AUC0-6 weeks. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Pre-dose and 1 hour post-dose during (week 0 to week 6) and (week 48 to week 54)

  92. Observed NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006)

    Ctrough of NNC0114-0006 was defined as concentration prior to dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Week 48 (predose)

  93. Observed NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006)

    C1h, NNC0114-0006 was defined as concentration of NNC0114-0006 at 1 hour after dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

    Time frame: Week 48 (1 hour post-dose)

  94. Liraglutide Concentration at Steady State (C Liraglutide)

    C liraglutide was defined as the liraglutide concentration at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and Liraglutide treatment arms.

    Time frame: Week 54 (post-dose)

  95. Change in Biomarker: Immune Phenotyping- B Cell Panel

    B cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; IgMNeg refers to Immunoglobulin M negative; IgDNeg refers to Immunoglobulin D negative.

    Time frame: Week 0, week 54 and week 80

  96. Change in Biomarker: Immune Phenotyping- Natural Killer (NK) Cell Panel

    NK cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table ADCC refer to Antibody-dependent cellular cytotoxicity; CD refer to Cluster of Differentiation.

    Time frame: Week 0, week 54 and week 80

  97. Change in Biomarker: Immune Phenotyping- T Cell Panel

    T cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; TEMRA refers to terminally differentiated effector memory cells re-expressing CD45RA; CCR refers to C-C chemokine receptor; TREG refers to Regulatory T cells.

    Time frame: Week 0, week 54 and week 80

  98. Change in Biomarker: Immune Phenotyping- T Follicular Helper (TfH) Cell Panel

    TfH cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CTFH refer to Circulating T follicular helper; ICOS refers to inducible T-cell co-stimulator; PD refers to Programmed cell death protein; CCR refers to C-C chemokine receptor; CXCR refers to C-X-C chemokine receptor; CD refer to Cluster of Differentiation; CM refers to central memory; EM refers to effector memory, TIGIT refers to T cell immunoreceptor with Ig and ITIM domains.

    Time frame: Week 0, week 54 and week 80

  99. Change in Biomarker: Immune Phenotyping- Myeloid Cell Panel

    Myeloid panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table HLA refers to Human Leukocyte Antigen; MDSC refers to myeloid-derived suppressor cell; DC refers to Dendritic cells; MYDC refers to Myeloid Dendritic Cells; IMMYE_MDSC refers to Immature myeloid cells \& a subset of myeloid suppressor cells within the CD14-HLA class II- myeloid cell population.

    Time frame: Week 0, week 54 and week 80

  100. Autoantibodies Against Glutamic Acid Decarboxylase (GAD)

    Participants were analyzed for autoantibodies against Glutamic acid decarboxylase (GAD) and were categorized as negative and positive.

    Time frame: Week 0, week 54 and week 80

  101. Autoantibodies Against Zinc-transporter 8 (ZnT8)

    Participants were analyzed for autoantibodies against Zinc-transporter 8 (ZnT8) and were categorized as negative and positive.

    Time frame: Week 0, week 54 and week 80

  102. Autoantibodies Against Islet Antigen-2 (IA2)

    Participants were analyzed for autoantibodies against Islet antigen-2 (IA2) and were categorized as negative and positive.

    Time frame: Week 0, week 54 and week 80

  103. Autoantibodies Against Insulin Autoantibodies (IAA)

    Participants were analyzed for autoantibodies against Insulin autoantibodies (IAA) and were categorized as negative and positive.

    Time frame: Week 0, week 54 and week 80

  104. Change in Biomarker: Total Interleukin-21 (IL-21)

    IL-21 is evaluated at baseline (week 0), week 54 and week 80.

    Time frame: Week 0, week 54 and week 80

  105. Change in Biomarker: Serum Vitamin D (1,25 Dehydroxy-calciferol)

    Serum vitamin D is evaluated at baseline (week 0), week 54 and week 80.

    Time frame: Week 0, week 54 and week 80

  106. Change in Short Form 36 Health Survey (SF-36)

    SF-36v2™ questionnaire measured the HRQoL on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. Change from baseline (week 0) to week 54 and week 80 in SF-36 score is presented.The MCS measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The PCS measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicate an improvement since baseline.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  107. Change in Experience of Treatment Benefits and Barriers (ETBB)

    Treatment Benefits and Barriers (ETBB) questionnaire measured diabetes-specific health beliefs on 2 categories: Total Score for Perceived Barriers and Perceived Benefits. The measurement of perceived benefits of, and barriers to, treatment was achieved by creating a pool 28 statements each with a 7-point scale ranging from strongly agree (6) to strongly disagree (0). ETBB benefits score was calculated using the responses from questions 1, 4, 7, 8, 10, and 12 and ETBB barriers score was calculated using the responses from questions 2, 3, 5, 6, 9, and 11. Both was calculated as the sum of responses divided by number of responses received multiplied by the maximum number of responses. Based on the responses used the maximum responses available was 6. The higher score indicates more perceived benefits or more perceived barrier.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  108. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ)

    Change from baseline (week 0) in DTSQ is evaluated at week 54 and 80. The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher score indicates a higher level of glycaemia/treatment satisfaction.

    Time frame: (Week 0, week 54) and (week 0, week 80)

  109. Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline

    Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).

    Time frame: 0 - 4 hours post-dose on week 0 and week 80

  110. AUC0-2h of C-peptide at Week 80 Relative to Baseline

    Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.

    Time frame: 0-2 hours post-dose on week 0 and week 80

  111. Cmax of C-peptide at Week 80 Relative to Baseline

    Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).

    Time frame: 0-4 hours post-dose on week 0 and week 80

  112. AUC0-4h of Glucose at Week 80 Relative to Baseline

    Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).

    Time frame: 0 - 4 hours post-dose on week 0 and week 80

  113. AUC0-2h of Glucose at Week 80 Relative to Baseline

    Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as 'mmol\*h/L'.

    Time frame: 0-2 hours post-dose on week 0 and week 80

  114. Cmax of Glucose at Week 80 Relative to Baseline

    Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.

    Time frame: 0-4 hours post-dose on week 0 and week 80

08

Results

Posted Jan 11, 2021

Participant flow

The trial was conducted at 94 sites in Austria, Belgium, Canada, Denmark, Finland, Ireland, Israel, Italy, Norway, Poland, Portugal, Russian Federation, Spain, Sweden, Ukraine, the United Kingdom (UK), and the United States (US).

Participant flow — Overall Study
MilestoneNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Started77777677
Full analysis set77777677
Pk analysis set21212220
Safety analysis set77777677
Completed65636761
Not completed1214916
Withdrew: Adverse event3412
Withdrew: Unclassified0021
Withdrew: Withdrawal by subject4739
Withdrew: Pregnancy3112
Withdrew: Lost to follow-up1201
Withdrew: Protocol violation1011
Withdrew: Death0010

Outcome measures

PrimaryArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline

Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).

Time frame:
0 - 4 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of AUC
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline0.934 ± 61.90.783 ± 45.50.709 ± 104.80.660 ± 86.3
Statistical analysis
  • NNC0114-0006 + Liraglutide (Experimental) vs Placebo (Placebo) · Mixed model repeated measurements · p = =0.0017 · Treatment ratio: 1.48 · 95% CI 1.16 to 1.89NNC0114-0006 + liraglutide / Placebo
  • NNC0114-0006 (Experimental) vs Placebo (Placebo) · Mixed model repeated measurements · p = =0.0927 · Treatment ratio: 1.23 · 95% CI 0.97 to 1.57
  • Liraglutide (Experimental) vs Placebo (Placebo) · Mixed model repeated measurements · p = =0.3780 · Treatment ratio: 1.12 · 95% CI 0.87 to 1.42
  • NNC0114-0006 + Liraglutide (Experimental) vs NNC0114-0006 (Experimental) · Mixed model repeated measurements · p = =0.1377 · Treatment ratio: 1.20 · 95% CI 0.94 to 1.53
  • NNC0114-0006 + Liraglutide (Experimental) vs Liraglutide (Experimental) · Mixed model repeated measurements · p = =0.0214 · Treatment ratio: 1.33 · 95% CI 1.04 to 1.69
  • NNC0114-0006 (Experimental) vs Liraglutide (Experimental) · Mixed model repeated measurements · p = =0.4187 · Treatmrnt ratio: 1.10 · 95% CI 0.87 to 1.41
SecondaryAUC0-2h of C-peptide at Week 54 Relative to Baseline

Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.

Time frame:
0-2 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of AUC
AUC0-2h of C-peptide at Week 54 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-2h of C-peptide at Week 54 Relative to Baseline0.961 ± 65.40.824 ± 53.00.646 ± 97.40.655 ± 87.3
SecondaryCmax of C-peptide at Week 54 Relative to Baseline

Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).

Time frame:
0-4 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of Cmax
Cmax of C-peptide at Week 54 Relative to Baseline
Ratio of CmaxNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Cmax of C-peptide at Week 54 Relative to Baseline0.978 ± 70.30.779 ± 47.60.733 ± 110.40.644 ± 89.4
SecondaryAUC0-4h of Glucose at Week 54 Relative to Baseline

Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).

Time frame:
0 - 4 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of AUC
AUC0-4h of Glucose at Week 54 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-4h of Glucose at Week 54 Relative to Baseline0.904 ± 33.11.078 ± 31.80.993 ± 34.21.089 ± 36.7
SecondaryAUC0-2h of Glucose at Week 54 Relative to Baseline

Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. AUC of glucose is measured as 'mmol\*h/L'.

Time frame:
0-2 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of AUC
AUC0-2h of Glucose at Week 54 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-2h of Glucose at Week 54 Relative to Baseline0.939 ± 28.51.066 ± 24.80.978 ± 31.91.057 ± 31.3
SecondaryCmax of Glucose at Week 54 Relative to Baseline

Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 54 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.

Time frame:
0-4 hours post-dose on week 0 and week 54
Reported as:
Geometric mean · Ratio of Cmax
Cmax of Glucose at Week 54 Relative to Baseline
Ratio of CmaxNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Cmax of Glucose at Week 54 Relative to Baseline0.937 ± 27.81.068 ± 25.41.004 ± 29.11.057 ± 30.9
SecondaryNumber of Treatment Emergent Adverse Events

An adverse event was any untoward medical occurrence in a participants administered a product, and which did not necessarily have a causal relationship with this treatment. An adverse event was defined as treatment emergent if the onset of the adverse event occurs on or after the first day of trial product administration. Number of treatment emergent adverse events from first dose of trial product to week 54 and week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

Time frame:
Week 0-54; Week 54-80
Reported as:
Number · Adverse events
Number of Treatment Emergent Adverse Events
Adverse eventsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0-54434327410364
Week 54-8070737887
SecondaryNumber of Treatment Emergent Hyperglycaemic Episodes

Hyperglycaemic episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

Time frame:
Week 0-54; Week 54-80
Reported as:
Number · Episodes
Number of Treatment Emergent Hyperglycaemic Episodes
EpisodesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0-54302256217291
Week 54-8030674352112
SecondaryNumber of Treatment Emergent Episodes of Diabetic Ketoacidosis

Diabetic ketoacidosis episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of treatment emergent episodes of hyperglycaemic episodes from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results are based on the on-treatment and on-observation period. On-treatment period: From the day of first trial product administration to the day of the visit at week 54. On-observation: From the day after the visit at week 54 to the day of the last visit.

Time frame:
Weeks 0-54; Weeks 54-80
Reported as:
Number · Episodes
Number of Treatment Emergent Episodes of Diabetic Ketoacidosis
EpisodesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0-540000
Week 54-800011
SecondaryNumber of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion

Injection/infusion site reactions episodes were defined as treatment-emergent if the onset occurred on or after the first day of trial product administration. Number of participants experiencing treatment emergent episodes of injection/infusion site reactions episodes from first dose of trial product to week 54 (treatment period) is presented.

Time frame:
Week 0-54
Reported as:
Count of participants · Participants
Number of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Number of Participants Experiencing Treatment Emergent Injection/Infusion Site Reactions Caused by NNC0114-0006/Liraglutide/Placebo Injection/Infusion2001
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA)

Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 1 day after the date of last contact. Number of treatment-emergent hypoglycaemic episodes according to American Diabetes Association (ADA) classification from first dose of trial product to week 54 and from week 54 to week 80 are presented. Results presented hypoglycaemia episodes were recorded as per ADA definition: Severe hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Pseudo-hypoglycaemia.

Time frame:
Weeks 0-54; Weeks 54-80
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association (ADA)
EpisodesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Severe hypoglycaemia (Week 0-54)1200
Asymptomatic hypoglycaemia (Week 0-54)2038195620921774
Documented symptomatic hypoglycaemia (Week 0-54)1305146111141625
Pseudo-hypoglycaemia (Week 0-54)11142
Probable symptomatic hypoglycaemia (Week 0-54)90410
Severe hypoglycaemia (Week 54-80)3101
Asymptomatic hypoglycaemia (Week 54-80)609522670449
Documented symptomatic hypoglycaemia (Week 54-80)514362651527
Pseudo-hypoglycaemia (Week 54-80)0012
Probable symptomatic hypoglycaemia (Week 54-80)1002
SecondaryNumber of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk Definitions

Hypoglycaemia episodes were recorded as per Novo Nordisk definition: Symptomatic BG-confirmed: An episode that is blood glucose (BG) confirmed by plasma glucose (PG) value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. Asymptomatic BG-confirmed: An episode that is BG-confirmed by PG value \<3.1 mmol/L without symptoms consistent with hypoglycaemia. Severe or BG-confirmed symptomatic: An episode that is severe according to the ISPAD classification or BG-confirmed by a PG value \<3.1 mmol/L with symptoms consistent with hypoglycaemia. BG-confirmed: An episode that is BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Severe or BG-confirmed: An episode that is severe according to the International Society for Pediatric and Adolescent Diabetes (ISPAD) classification or BG-confirmed by a PG value \<3.1 mmol/L with or without symptoms consistent with hypoglycaemia.

Time frame:
Weeks 0-54; Weeks 54-80
Reported as:
Number · Episodes
Number of Treatment Emergent Hypoglycaemic Episodes According to Novo Nordisk Definitions
EpisodesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Severe or BG confirmed (Week 0-54)396394315503
Symptomatic BG confirmed (Week 0-54)576616479646
Severe or BG confirmed (Week 54-80)216130244240
Symptomatic BG confirmed (Week 54-80)368207332292
SecondaryChange in Body Weight (kg)

Change in body weight is measured at week 54 and week 80 respective to baseline. Body weight was measured in unit 'Kg'.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Kilogram (Kg)
Change in Body Weight (kg)
Kilogram (Kg)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-1.8 ± 4.21.2 ± 5.0-2.5 ± 4.01.1 ± 6.1
Change from week 0 to week 801.9 ± 4.61.6 ± 5.20.4 ± 4.72.8 ± 5.5
SecondaryDiabetes Retinopathy

Number of participants evaluated for diabetic retinopathy at baseline (Day -28 to -14), week 54 and week 80 are presented as 'yes', 'no' or 'unknown'.

Time frame:
Baseline, week 54 and week 80
Reported as:
Count of participants · Participants
Diabetes Retinopathy
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Baseline (Day:-28 to -14) — Yes4211
Baseline (Day:-28 to -14) — No73757576
Baseline (Day:-28 to -14) — Unknown0000
Week 54 — Yes3210
Week 54 — No65636868
Week 54 — Unknown0000
Week 80 — Yes3210
Week 80 — No65626763
Week 80 — Unknown1111
SecondaryEstimated Glomerular Filtration Rate (eGFR)- Ratio to Baseline

The eGFR was measured using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. Change in eGFR (measured in milliliters per minute per 1.73 square meters) from baseline (week 0) at week 54 and week 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of eGFR
Estimated Glomerular Filtration Rate (eGFR)- Ratio to Baseline
Ratio of eGFRNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.98 ± 10.30.95 ± 8.20.97 ± 10.21.00 ± 8.8
Change from week 0 to week 800.97 ± 9.30.94 ± 11.40.96 ± 11.50.99 ± 10.9
SecondaryChange in Haematology: Erythrocytes

Change in erythrocytes (measured in 10\^12 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of erythrocytes
Change in Haematology: Erythrocytes
ratio of erythrocytesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 6.001.01 ± 6.30.99 ± 7.21.00 ± 6.0
Change from week 0 to week 800.99 ± 6.71.00 ± 6.70.99 ± 7.001.00 ± 5.5
SecondaryChange in Haematology: Haematocrit

Change in haematocrit (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of haematocrit
Change in Haematology: Haematocrit
ratio of haematocritNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 6.61.00 ± 7.000.99 ± 7.81.00 ± 5.9
Change from week 0 to week 800.98 ± 7.51.00 ± 7.30.98 ± 7.20.99 ± 5.8
SecondaryChange in Haematology: Haemoglobin

Change in haemoglobin (measured in millimoles per liter 'mmol/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of haemoglobin
Change in Haematology: Haemoglobin
ratio of haemoglobinNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.01 ± 6.11.02 ± 7.21.00 ± 7.91.01 ± 5.6
Change from week 0 to week 801.00 ± 7.51.02 ± 8.21.00 ± 7.41.01 ± 5.6
SecondaryChange in Haematology: Leukocytes

Change in leukocytes (measured in 10\^9 cells/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of leukocytes
Change in Haematology: Leukocytes
ratio of leukocytesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.96 ± 27.10.98 ± 21.90.97 ± 23.21.02 ± 24.8
Change from week 0 to week 800.99 ± 33.00.95 ± 19.90.99 ± 29.51.00 ± 24.9
SecondaryChange in Haematology: Mean Corpuscular Hemoglobin

Change in mean Corpuscular hemoglobin (measured in femtomole 'fmol') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · ratio of mean Corpuscular hemoglobin
Change in Haematology: Mean Corpuscular Hemoglobin
ratio of mean Corpuscular hemoglobinNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.02 ± 3.61.01 ± 4.81.01 ± 4.01.01 ± 4.1
Change from week 0 to week 801.02 ± 5.11.01 ± 6.61.01 ± 5.41.02 ± 4.3
SecondaryChange in Haematology: Mean Corpuscular Hemoglobin Concentration

Change in mean corpuscular hemoglobin concentration (MCHC) (measured in gram per liter 'g/L') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of MCHC
Change in Haematology: Mean Corpuscular Hemoglobin Concentration
Ratio of MCHCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.02 ± 2.91.01 ± 2.11.02 ± 2.61.02 ± 3.0
Change from week 0 to week 801.02 ± 3.51.02 ± 3.11.02 ± 3.01.02 ± 0.29
SecondaryChange in Haematology: Mean Corpuscular Volume

Change in Mean Corpuscular volume (measured in femtoliter 'fL') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of mean corpuscular volume
Change in Haematology: Mean Corpuscular Volume
ratio of mean corpuscular volumeNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 2.80.99 ± 3.81.00 ± 3.30.99 ± 3.3
Change from week 0 to week 801.00 ± 4.31.00 ± 5.21.00 ± 4.30.99 ± 3.7
SecondaryChange in Haematology: Thrombocytes

Change in thrombocytes (measured in 10\^9 cells per liter) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of thrombocytes
Change in Haematology: Thrombocytes
ratio of thrombocytesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.98 ± 14.50.98 ± 15.01.03 ± 13.20.98 ± 14.1
Change from week 0 to week 801.00 ± 15.01.03 ± 15.71.04 ± 15.61.00 ± 17.3
SecondaryChange in Haematology: Eosinophil

Change in eosinophil (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Ratio of eosinophils
Change in Haematology: Eosinophil
Ratio of eosinophilsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.15 ± 0.651.30 ± 1.713.10 ± 13.791.37 ± 1.15
Change from week 0 to week 801.31 ± 1.241.23 ± 1.031.54 ± 1.781.36 ± 1.27
SecondaryChange in Haematology: Neutrophils

Change in neutrophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of neutrophils
Change in Haematology: Neutrophils
ratio of neutrophilsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.98 ± 18.80.99 ± 17.60.97 ± 18.51.04 ± 17.8
Change from week 0 to week 800.97 ± 17.50.99 ± 14.20.98 ± 20.71.04 ± 17.2
SecondaryChange in Haematology: Basophils

Change in basophils (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Ratio of basophils
Change in Haematology: Basophils
Ratio of basophilsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.73 ± 2.111.58 ± 1.521.52 ± 1.471.43 ± 1.06
Change from week 0 to week 802.17 ± 2.171.73 ± 1.412.09 ± 1.861.96 ± 1.27
SecondaryChange in Haematology: Lymphocytes

Change in lymphocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of lymphocytes
Change in Haematology: Lymphocytes
ratio of lymphocytesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 28.51.00 ± 28.31.02 ± 28.40.91 ± 30.7
Change from week 0 to week 801.01 ± 28.00.98 ± 21.80.99 ± 35.10.91 ± 30.6
SecondaryChange in Haematology: Monocytes

Change in monocytes (measured in percentage '%') from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of monocytes
Change in Haematology: Monocytes
ratio of monocytesNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.05 ± 40.81.02 ± 34.81.01 ± 41.11.01 ± 34.9
Change from week 0 to week 801.12 ± 44.01.07 ± 37.51.04 ± 42.91.12 ± 35.4
SecondaryChange in Biochemistry: Alanine Aminotransferase (ALAT)

Change in ALAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of ALT
Change in Biochemistry: Alanine Aminotransferase (ALAT)
ratio of ALTNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.96 ± 47.70.98 ± 35.90.97 ± 46.00.90 ± 44.1
Change from week 0 to week 800.95 ± 54.70.98 ± 39.51.06 ± 40.70.92 ± 40.6
SecondaryChange in Biochemistry: Albumin

Change in albumin (measured in gram per deciliter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · ratio of albumin
Change in Biochemistry: Albumin
ratio of albuminNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 7.31.00 ± 6.001.02 ± 7.40.99 ± 7.5
Change from week 0 to week 801.00 ± 6.71.01 ± 6.91.00 ± 6.70.99 ± 6.9
SecondaryChange in Biochemistry: Amylase

Change in amylase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of Amylase
Change in Biochemistry: Amylase
ratio of AmylaseNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.07 ± 20.70.98 ± 16.61.04 ± 18.91.01 ± 19.2
Change from week 0 to week 801.04 ± 24.30.99 ± 14.91.03 ± 19.81.04 ± 26.1
SecondaryChange in Biochemistry: Alkaline Phosphatase (ALP)

Change in ALP (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of ALP
Change in Biochemistry: Alkaline Phosphatase (ALP)
Ratio of ALPNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.03 ± 28.60.99 ± 17.80.99 ± 18.11.03 ± 17.9
Change from week 0 to week 801.07 ± 30.31.05 ± 16.51.04 ± 22.11.04 ± 21.7
SecondaryChange in Biochemistry: Aspartate Aminotransferase (ASAT)

Change in ASAT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of AST
Change in Biochemistry: Aspartate Aminotransferase (ASAT)
Ratio of ASTNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 39.30.99 ± 34.51.00 ± 57.00.98 ± 43.1
Change from week 0 to week 800.98 ± 39.10.98 ± 32.41.09 ± 34.60.99 ± 39.3
SecondaryChange in Biochemistry: Total Bilirubin

Change in Total bilirubin (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of total bilirubin
Change in Biochemistry: Total Bilirubin
ratio of total bilirubinNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.81 ± 61.71.10 ± 56.50.99 ± 49.81.01 ± 59.4
Change from week 0 to week 800.91 ± 44.71.04 ± 74.80.98 ± 55.10.99 ± 58.7
SecondaryChange in Biochemistry: Calcium Corrected

Change in calcium corrected (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of calcium
Change in Biochemistry: Calcium Corrected
ratio of calciumNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 3.70.98 ± 3.60.98 ± 4.00.99 ± 4.2
Change from week 0 to week 800.96 ± 3.50.97 ± 4.00.98 ± 3.90.98 ± 4.0
SecondaryChange in Biochemistry: Chloride

Change in chloride (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · ratio of chloride
Change in Biochemistry: Chloride
ratio of chlorideNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.01 ± 2.41.00 ± 2.21.00 ± 2.81.00 ± 3.1
Change from week 0 to week 801.00 ± 2.31.01 ± 2.71.00 ± 3.01.00 ± 3.0
SecondaryChange in Biochemistry: Creatine Kinase

Change in creatine kinase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Creatine Kinase
Change in Biochemistry: Creatine Kinase
Ratio of Creatine KinaseNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.16 ± 86.31.17 ± 64.51.08 ± 140.21.02 ± 72.8
Change from week 0 to week 801.11 ± 48.11.09 ± 68.31.24 ± 87.21.13 ± 76.5
SecondaryChange in Biochemistry: Creatinine

Change in creatinine (measured in micromole per liter \[umol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Creatinine
Change in Biochemistry: Creatinine
Ratio of CreatinineNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.01 ± 12.01.05 ± 10.61.04 ± 12.81.01 ± 9.9
Change from week 0 to week 801.02 ± 11.21.05 ± 14.31.05 ± 13.11.02 ± 12.3
SecondaryChange in Biochemistry: Gamma-glutamyl Transferase (GGT)

Change in GGT (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of GGT
Change in Biochemistry: Gamma-glutamyl Transferase (GGT)
Ratio of GGTNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.02 ± 38.61.08 ± 27.71.03 ± 37.21.02 ± 41.8
Change from week 0 to week 801.05 ± 41.91.13 ± 29.41.10 ± 41.11.00 ± 36.8
SecondaryChange in Biochemistry: C-reactive Protein Serum

Change in C-reactive protein serum (measured in milligrams per liter \[mg/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of C-reactive protein
Change in Biochemistry: C-reactive Protein Serum
Ratio of C-reactive proteinNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.92 ± 141.61.04 ± 93.00.89 ± 87.81.06 ± 78.0
Change from week 0 to week 801.08 ± 103.80.94 ± 81.01.25 ± 134.71.06 ± 70.1
SecondaryChange in Biochemistry: Lactate Dehydrogenase

Change in Lactate Dehydrogenase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Lactate Dehydrogenase
Change in Biochemistry: Lactate Dehydrogenase
Ratio of Lactate DehydrogenaseNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 12.61.03 ± 18.41.04 ± 23.31.03 ± 16.5
Change from week 0 to week 801.02 ± 12.11.04 ± 19.61.09 ± 19.31.03 ± 17.8
SecondaryChange in Biochemistry: Lipase

Change in lipase (measured in units per liter \[U/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of lipase
Change in Biochemistry: Lipase
Ratio of lipaseNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.49 ± 36.61.00 ± 27.41.34 ± 36.21.01 ± 29.4
Change from week 0 to week 801.05 ± 40.40.94 ± 27.21.02 ± 26.50.96 ± 37.2
SecondaryChange in Biochemistry: Magnesium

Change in magnesium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of magnesium
Change in Biochemistry: Magnesium
Ratio of magnesiumNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.02 ± 8.91.01 ± 7.61.02 ± 7.80.99 ± 8.1
Change from week 0 to week 801.01 ± 10.71.03 ± 11.21.02 ± 9.00.98 ± 9.2
SecondaryChange in Biochemistry: Phosphate

Change in phosphate (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of phosphate
Change in Biochemistry: Phosphate
Ratio of phosphateNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 16.00.99 ± 16.61.02 ± 13.90.96 ± 18.6
Change from week 0 to week 801.02 ± 20.51.01 ± 16.91.03 ± 19.90.99 ± 17.4
SecondaryChange in Biochemistry: Potassium

Change in potassium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of potassium
Change in Biochemistry: Potassium
Ratio of potassiumNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.01 ± 8.10.98 ± 6.90.99 ± 8.30.98 ± 10.4
Change from week 0 to week 800.99 ± 8.30.99 ± 6.90.98 ± 8.50.98 ± 10.0
SecondaryChange in Biochemistry: Sodium

Change in sodium (measured in millimole per liter \[mmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of sodium
Change in Biochemistry: Sodium
Ratio of sodiumNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 1.91.00 ± 1.41.00 ± 1.91.00 ± 2.0
Change from week 0 to week 800.99 ± 1.81.00 ± 2.11.00 ± 2.31.00 ± 1.8
SecondaryChange in Biochemistry: Total Protein

Change in total protein (measured in gram per liter \[g/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of total protein
Change in Biochemistry: Total Protein
Ratio of total proteinNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.99 ± 6.81.00 ± 6.01.01 ± 7.21.00 ± 7.6
Change from week 0 to week 800.99 ± 6.51.00 ± 6.41.00 ± 6.61.00 ± 7.4
SecondaryChange in Biochemistry: Blood Urea Nitrogen Serum

Change in blood urea nitrogen serum (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Blood Urea Nitrogen serum
Change in Biochemistry: Blood Urea Nitrogen Serum
Ratio of Blood Urea Nitrogen serumNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 27.01.05 ± 22.40.98 ± 22.00.94 ± 23.3
Change from week 0 to week 800.97 ± 33.20.97 ± 26.20.98 ± 28.90.97 ± 28.2
SecondaryChange in Biochemistry: Uric Acid

Change in Uric Acid (measured in milligram per deciliter \[mg/dL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of uric acid
Change in Biochemistry: Uric Acid
Ratio of uric acidNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.93 ± 21.30.98 ± 17.60.98 ± 18.80.96 ± 18.0
Change from week 0 to week 800.95 ± 17.10.94 ± 19.10.96 ± 22.20.95 ± 19.6
SecondaryChange in International Normalised Ratio (INR)

Change in INR (measured in ratio\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of INR
Change in International Normalised Ratio (INR)
Ratio of INRNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.97 ± 9.50.96 ± 10.40.95 ± 9.80.96 ± 13.7
Change from week 0 to week 800.98 ± 12.40.99 ± 12.90.96 ± 9.20.97 ± 11.5
SecondaryChange in D-Dimer

Change in D-Dimer (measured in mg/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of D-dimer
Change in D-Dimer
Ratio of D-dimerNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.96 ± 37.60.98 ± 53.90.98 ± 56.81.15 ± 107.1
Change from week 0 to week 800.96 ± 43.70.92 ± 61.31.05 ± 60.01.10 ± 74.3
SecondaryChange in Lipids: Total Cholesterol (Ratio to Baseline)

Change in total cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of total cholesterol
Change in Lipids: Total Cholesterol (Ratio to Baseline)
Ratio of total cholesterolNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 13.81.02 ± 14.11.03 ± 16.21.04 ± 16.8
Change from week 0 to week 801.02 ± 15.51.03 ± 14.11.07 ± 15.01.03 ± 18.4
SecondaryChange in Lipids: Free Fatty Acids (Ratio to Baseline)

Change in total free fatty acids (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of free fatty acids
Change in Lipids: Free Fatty Acids (Ratio to Baseline)
Ratio of free fatty acidsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.86 ± 94.51.01 ± 114.41.18 ± 82.50.97 ± 68.7
Change from week 0 to week 800.89 ± 85.31.06 ± 112.81.19 ± 92.80.94 ± 84.0
SecondaryChange in Lipids: HDL Cholesterol (Ratio to Baseline)

Change in HDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of HDL cholesterol
Change in Lipids: HDL Cholesterol (Ratio to Baseline)
Ratio of HDL cholesterolNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.04 ± 17.31.08 ± 18.21.12 ± 19.61.10 ± 20.2
Change from week 0 to week 801.04 ± 18.71.06 ± 16.71.14 ± 21.51.07 ± 22.2
SecondaryChange in Lipids: LDL Cholesterol (Ratio to Baseline)

Change in LDL cholesterol (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of LDL cholesterol
Change in Lipids: LDL Cholesterol (Ratio to Baseline)
Ratio of LDL cholesterolNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.96 ± 17.80.97 ± 20.90.98 ± 24.01.01 ± 23.6
Change from week 0 to week 800.99 ± 22.21.02 ± 21.21.02 ± 21.21.03 ± 29.2
SecondaryChange in Lipids: Triglycerides (TG) (Ratio to Baseline)

Change in Triglycerides (measured in mmol/L) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of TG
Change in Lipids: Triglycerides (TG) (Ratio to Baseline)
Ratio of TGNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.03 ± 46.20.96 ± 39.51.03 ± 49.21.02 ± 54.7
Change from week 0 to week 801.08 ± 45.60.94 ± 45.11.09 ± 51.50.95 ± 50.4
SecondaryChange in Total Immunoglobulin E (IgE)

Change in IgE (measured in kilo international units per liter \[kIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of IgE
Change in Total Immunoglobulin E (IgE)
Ratio of IgENNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.31 ± 71.61.05 ± 63.11.08 ± 45.71.02 ± 41.8
Change from week 0 to week 801.32 ± 65.41.18 ± 38.51.16 ± 55.10.94 ± 61.2
SecondaryChange in Urinalysis: Urine Dipsticks

Urinalysis was performed by urine dipsticks for protein, glucose, erythrocytes, ketones leukocytes, nitrite, pH and specific gravity and categorised as normal, abnormal not clinically significant (NCS) and abnormal clinially significant (CS). Number of participants in each category at baseline (week 0), week 54 and 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Change in Urinalysis: Urine Dipsticks
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: Glucose dipstick — Normal72716771
Week 0: Glucose dipstick — Abnormal, NCS5696
Week 0: Glucose dipstick — Abnormal, CS0000
Week 54: Glucose dipstick — Normal57566359
Week 54: Glucose dipstick — Abnormal, NCS9956
Week 54: Glucose dipstick — Abnormal, CS2000
Week 80: Glucose dipstick — Normal54545451
Week 80: Glucose dipstick — Abnormal, NCS12101311
Week 80: Glucose dipstick — Abnormal, CS0010
Week 0: Ketone dipstick — Normal74737376
Week 0: Ketone dipstick — Abnormal, NCS2431
Week 0: Ketone dipstick — Abnormal, CS1000
Week 54: Ketone dipstick — Normal68646564
Week 54: Ketone dipstick — Abnormal, NCS0131
Week 54: Ketone dipstick — Abnormal, CS0000
Week 80: Ketone dipstick — Normal65616661
Week 80: Ketone dipstick — Abnormal, NCS1311
Week 80: Ketone dipstick — Abnormal, CS0010
Week 0: pH dipstick — Normal75777675
Week 0: pH dipstick — Abnormal, NCS2002
Week 0: pH dipstick — Abnormal, CS0000
Week 54: pH dipstick — Normal67656864
Week 54: pH dipstick — Abnormal, NCS1001
Week 54: pH dipstick — Abnormal, CS0000
Week 80: pH dipstick — Normal66646862
Week 80: pH dipstick — Abnormal, NCS0000
Week 80: pH dipstick — Abnormal, CS0000
Week 0: Erythrocytes in urine — Normal74747472
Week 0: Erythrocytes in urine — Abnormal, NCS2324
Week 0: Erythrocytes in urine — Abnormal, CS1001
Week 54: Erythrocytes in urine — Normal66636663
Week 54: Erythrocytes in urine — Abnormal, NCS2222
Week 54: Erythrocytes in urine — Abnormal, CS0000
Week 80: Erythrocytes in urine — Normal63616560
Week 80: Erythrocytes in urine — Abnormal, NCS3332
Week 80: Erythrocytes in urine — Abnormal, CS0000
Week 0: Leukocytes in urine — Normal77737677
Week 0: Leukocytes in urine — Abnormal, NCS0400
Week 0: Leukocytes in urine — Abnormal, CS0000
Week 54: Leukocytes in urine — Normal64626764
Week 54: Leukocytes in urine — Abnormal, NCS4311
Week 54: Leukocytes in urine — Abnormal, CS0000
Week 80: Leukocytes in urine — Normal62616760
Week 80: Leukocytes in urine — Abnormal, NCS4312
Week 80: Leukocytes in urine — Abnormal, CS0000
Week 0: Nitrite — Normal77777677
Week 0: Nitrite — Abnormal, NCS0000
Week 0: Nitrite — Abnormal, CS0000
Week 54: Nitrite — Normal68656865
Week 54: Nitrite — Abnormal, NCS0000
Week 54: Nitrite — Abnormal, CS0000
Week 80: Nitrite — Normal65646861
Week 80: Nitrite — Abnormal, NCS1001
Week 80: Nitrite — Abnormal, CS0000
Week 0: Protein urine — Normal77717576
Week 0: Protein urine — Abnormal, NCS0611
Week 0: Protein urine — Abnormal, CS0000
Week 54: Protein urine — Normal67646261
Week 54: Protein urine — Abnormal, NCS1164
Week 54: Protein urine — Abnormal, CS0000
Week 80: Protein urine — Normal63626559
Week 80: Protein urine — Abnormal, NCS3132
Week 80: Protein urine — Abnormal, CS0101
Week 0: Specific Gravity — Normal75777675
Week 0: Specific Gravity — Abnormal, NCS2002
Week 0: Specific Gravity — Abnormal, CS0000
Week 54: Specific Gravity — Normal67656864
Week 54: Specific Gravity — Abnormal, NCS1001
Week 54: Specific Gravity — Abnormal, CS0000
Week 80: Specific Gravity — Normal65646862
Week 80: Specific Gravity — Abnormal, NCS1000
Week 80: Specific Gravity — Abnormal, CS0000
SecondaryChange in Cytokines: Interleukin (IL)-6

IL-6 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · picogram per milliliter (pg/mL)
Change in Cytokines: Interleukin (IL)-6
picogram per milliliter (pg/mL)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 00.9 ± 0.60.8 ± 0.11.2 ± 1.80.8 ± 0.3
Week 540.8 ± 0.30.8 ± 0.41.0 ± 0.80.8 ± 0.2
Week 800.9 ± 0.40.8 ± 0.20.9 ± 0.80.9 ± 0.4
SecondaryChange in Cytokines- Interleukin (IL)-10

IL-10 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · pg/mL
Change in Cytokines- Interleukin (IL)-10
pg/mLNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 00.7 ± 1.40.5 ± 1.10.4 ± 0.30.4 ± 0.2
Week 540.4 ± 0.20.4 ± 0.10.4 ± 0.30.4 ± 0.3
Week 800.4 ± 0.50.4 ± 0.20.5 ± 0.70.4 ± 0.1
SecondaryChange in Cytokines: Interleukin (IL)-17

IL-17 levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · pg/mL
Change in Cytokines: Interleukin (IL)-17
pg/mLNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 04.9 ± 2.04.7 ± 0.74.7 ± 0.04.8 ± 0.9
Week 544.9 ± 1.94.8 ± 1.35.1 ± 3.55.4 ± 5.0
Week 804.9 ± 1.74.7 ± 0.04.8 ± 1.24.8 ± 1.0
SecondaryChange in Cytokines: Interferon (IFN) Gamma

IFN gamma levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · pg/mL
Change in Cytokines: Interferon (IFN) Gamma
pg/mLNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 07.3 ± 16.17.8 ± 24.05.8 ± 11.64.3 ± 2.8
Week 544.6 ± 4.27.5 ± 19.65.0 ± 6.85.8 ± 7.0
Week 804.4 ± 2.84.9 ± 6.413.0 ± 57.54.5 ± 3.4
SecondaryChange in Cytokines: TNF-alpha

TNF-alpha levels at baseline (week 0), weeks 54 and 80 are evaluated and presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · pg/mL
Change in Cytokines: TNF-alpha
pg/mLNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 02.60 ± 1.692.32 ± 0.822.70 ± 1.733.06 ± 3.75
Week 542.36 ± 0.752.33 ± 0.592.56 ± 1.112.43 ± 0.65
Week 802.43 ± 0.662.36 ± 0.682.96 ± 2.392.75 ± 2.47
SecondaryChange in Hormone Level: Thyroid Stimulating Hormone (TSH)

Change in TSH (measured in milli international units per liter \[mIU/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Thyroid Stimulating Hormone
Change in Hormone Level: Thyroid Stimulating Hormone (TSH)
Ratio of Thyroid Stimulating HormoneNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 49.91.12 ± 54.10.89 ± 46.60.91 ± 66.1
Change from week 0 to week 801.04 ± 46.70.99 ± 116.10.99 ± 48.50.93 ± 84.5
SecondaryChange in Hormone Level: Calcitonin

Change in Calcitonin (measured in nanogram per liter \[ng/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of Calcitonin
Change in Hormone Level: Calcitonin
Ratio of CalcitoninNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 541.00 ± 43.50.90 ± 48.50.89 ± 57.20.88 ± 47.4
Change from week 0 to week 800.85 ± 50.90.93 ± 41.80.82 ± 71.50.90 ± 64.5
SecondaryChange in Systolic and Diastolic Blood Pressure

Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) are evaluated from baseline (week 0) to weeks 54 and 80.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Systolic and Diastolic Blood Pressure
Millimeters of mercury (mmHg)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 54: Systolic blood pressure-3 ± 93 ± 9-2 ± 141 ± 11
Week 80: Systolic blood pressure-1 ± 102 ± 111 ± 124 ± 10
Week 54: Diastolic blood pressure-0 ± 92 ± 9-1 ± 10-1 ± 8
Week 80: Diastolic blood pressure-0 ± 92 ± 91 ± 101 ± 10
SecondaryChange in Pulse

Change in pulse is evaluated from baseline (week 0) to weeks 54 and 80

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Beats/min
Change in Pulse
Beats/minNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 543 ± 120 ± 126 ± 92 ± 8
Change from week 0 to week 80-1 ± 10-1 ± 102 ± 101 ± 9
SecondaryChange in Body Temperature

Change in body temperature is evaluated from baseline (week 0) to weeks 54 and 80.

Time frame:
Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Degree celsius (C)
Change in Body Temperature
Degree celsius (C)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-0.1 ± 0.40.0 ± 0.6-0.1 ± 0.5-0.0 ± 0.3
Change from week 0 to week 80-0.0 ± 0.40.1 ± 0.50.0 ± 0.50.0 ± 0.4
SecondaryChange in Respiratory Rate

Change in respiratory rate is evaluated from baseline (week 0) to weeks 54 and 80.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Breaths per minute
Change in Respiratory Rate
Breaths per minuteNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-0.3 ± 2.20.1 ± 3.00.1 ± 2.50.6 ± 2.4
Change from week 0 to week 80-0.3 ± 2.0-0.2 ± 2.70.1 ± 2.50.1 ± 2.2
SecondaryChange in Electrocardiogram (ECG)

The ECG was assessed by the investigator at baseline (week 0), week 54 and week 80 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline, week 54 and week 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Change in Electrocardiogram (ECG)
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 — Normal62656063
Week 0 — Abnormal, NCS15121613
Week 0 — Abnormal, CS0001
Week 54 — Normal54485546
Week 54 — Abnormal, NCS14171219
Week 54 — Abnormal, CS0000
Week 80 — Normal51485350
Week 80 — Abnormal, NCS15161512
Week 80 — Abnormal, CS0000
SecondaryChange in Eye-examination

Dilated fundoscopy or fundus photography was performed by the investigator at week 0, week 54 and week 80. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week 0, week 54 and week 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Change in Eye-examination
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: Left eye ophthalmoscopy — Normal64687066
Week 0: Left eye ophthalmoscopy — Abnormal, NCS139611
Week 0: Left eye ophthalmoscopy — Abnormal, CS0000
Week 54: Left eye ophthalmoscopy — Normal55566054
Week 54: Left eye ophthalmoscopy — Abnormal, NCS12799
Week 54: Left eye ophthalmoscopy — Abnormal, CS1001
Week 80: Left eye ophthalmoscopy — Normal52545951
Week 80: Left eye ophthalmoscopy — Abnormal, NCS11868
Week 80: Left eye ophthalmoscopy — Abnormal, CS3000
Week 0: Right eye ophthalmoscopy — Normal58666967
Week 0: Right eye ophthalmoscopy — Abnormal, NCS1811710
Week 0: Right eye ophthalmoscopy — Abnormal, CS1000
Week 54: Right eye ophthalmoscopy — Normal55556055
Week 54: Right eye ophthalmoscopy — Abnormal, NCS13898
Week 54: Right eye ophthalmoscopy — Abnormal, CS0001
Week 80: Right eye ophthalmoscopy — Normal52535851
Week 80: Right eye ophthalmoscopy — Abnormal, NCS12978
Week 80: Right eye ophthalmoscopy — Abnormal, CS2000
SecondaryChange in Physical Examination

Physical examination parameters are categorised as general appearance; head, ears, eyes, nose, throat, neck; respiratory system;cardiovascular system; gastrointestinal system including mouth; musculoskeletal system; central and peripheral nervous system; skin; lymph node palpation and thyroid gland. Investigator assessed the participants with normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) findings at week 0, week 54 and week 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Change in Physical Examination
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: General Appearance — Normal76777676
Week 0: General Appearance — Abnormal, NCS1001
Week 0: General Appearance — Abnormal, CS0000
Week 54: General Appearance — Normal68646665
Week 54: General Appearance — Abnormal, NCS0001
Week 54: General Appearance — Abnormal, CS0100
Week 80: General Appearance — Normal67646861
Week 80: General Appearance — Abnormal, NCS0001
Week 80: General Appearance — Abnormal, CS0000
Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Normal75777676
Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS2001
Week 0: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS0000
Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Normal66656666
Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS1000
Week 54: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS1000
Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Normal65646660
Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, NCS2022
Week 80: Head, Ears, Eyes, Nose, Throat, Neck — Abnormal, CS0000
Week 0: Respiratory System — Normal77777677
Week 0: Respiratory System — Abnormal, NCS0000
Week 0: Respiratory System — Abnormal, CS0000
Week 54: Respiratory System — Normal68656666
Week 54: Respiratory System — Abnormal, NCS0000
Week 54: Respiratory System — Abnormal, CS0000
Week 80: Respiratory System — Normal67646861
Week 80: Respiratory System — Abnormal, NCS0001
Week 80: Respiratory System — Abnormal, CS0000
Week 0: Cardiovascular System — Normal74767673
Week 0: Cardiovascular System — Abnormal, NCS3104
Week 0: Cardiovascular System — Abnormal, CS0000
Week 54: Cardiovascular System — Normal67656566
Week 54: Cardiovascular System — Abnormal, NCS1010
Week 54: Cardiovascular System — Abnormal, CS0000
Week 80: Cardiovascular System — Normal67646762
Week 80: Cardiovascular System — Abnormal, NCS0010
Week 80: Cardiovascular System — Abnormal, CS0000
Week 0: Gastrointestinal System incl. Mouth — Normal75767676
Week 0: Gastrointestinal System incl. Mouth — Abnormal, NCS2101
Week 0: Gastrointestinal System incl. Mouth — Abnormal, CS0000
Week 54: Gastrointestinal System incl. Mouth — Normal68646665
Week 54: Gastrointestinal System incl. Mouth — Abnormal, NCS0101
Week 54: Gastrointestinal System incl. Mouth — Abnormal, CS0000
Week 80: Gastrointestinal System incl. Mouth — Normal67636861
Week 80: Gastrointestinal System incl. Mouth — Abnormal, NCS0101
Week 80: Gastrointestinal System incl. Mouth — Abnormal, CS0000
Week 0: Musculoskeletal System — Normal76757477
Week 0: Musculoskeletal System — Abnormal, NCS1220
Week 0: Musculoskeletal System — Abnormal, CS0000
Week 54: Musculoskeletal System — Normal65636665
Week 54: Musculoskeletal System — Abnormal, NCS1201
Week 54: Musculoskeletal System — Abnormal, CS2000
Week 80: Musculoskeletal System — Normal66646862
Week 80: Musculoskeletal System — Abnormal, NCS1000
Week 80: Musculoskeletal System — Abnormal, CS0000
Week 0: Central and Peripheral Nervous System — Normal77767676
Week 0: Central and Peripheral Nervous System — Abnormal, NCS0101
Week 0: Central and Peripheral Nervous System — Abnormal, CS0000
Week 54: Central and Peripheral Nervous System — Normal68646665
Week 54: Central and Peripheral Nervous System — Abnormal, NCS0101
Week 54: Central and Peripheral Nervous System — Abnormal, CS0000
Week 80: Central and Peripheral Nervous System — Normal66636862
Week 80: Central and Peripheral Nervous System — Abnormal, NCS1100
Week 80: Central and Peripheral Nervous System — Abnormal, CS0000
Week 0: Skin — Normal70756974
Week 0: Skin — Abnormal, NCS6273
Week 0: Skin — Abnormal, CS1000
Week 54: Skin — Normal61636366
Week 54: Skin — Abnormal, NCS5130
Week 54: Skin — Abnormal, CS2100
Week 80: Skin — Normal61626562
Week 80: Skin — Abnormal, NCS6230
Week 80: Skin — Abnormal, CS0000
Week 0: Lymph Node Palpation — Normal77767677
Week 0: Lymph Node Palpation — Abnormal, NCS0100
Week 0: Lymph Node Palpation — Abnormal, CS0000
Week 54: Lymph Node Palpation — Normal68656664
Week 54: Lymph Node Palpation — Abnormal, NCS0001
Week 54: Lymph Node Palpation — Abnormal, CS0000
Week 80: Lymph Node Palpation — Normal67636762
Week 80: Lymph Node Palpation — Abnormal, NCS0010
Week 80: Lymph Node Palpation — Abnormal, CS0000
Week 0: Thyroid Gland — Normal77767675
Week 0: Thyroid Gland — Abnormal, NCS0102
Week 0: Thyroid Gland — Abnormal, CS0000
Week 54: Thyroid Gland — Normal67656665
Week 54: Thyroid Gland — Abnormal, NCS1000
Week 54: Thyroid Gland — Abnormal, CS0000
Week 80: Thyroid Gland — Normal67646862
Week 80: Thyroid Gland — Abnormal, NCS0000
Week 80: Thyroid Gland — Abnormal, CS0000
SecondaryOccurrence of Anti-NNC0114-0006 Antibodies

This outcome measure was applicable for NNC0114-0006 + Liraglutide treatment arm and NNC0114-0006 treatment arm. Participants was assessed for anti-NNC0114-0006 antibodies. Participant who reported anti-NNC0114-0006 antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-NNC0114-0006 antibodies at week 54 and week 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Occurrence of Anti-NNC0114-0006 Antibodies
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Week 0: Anti-NNC0114-0006 antibodies — Negative6862
Week 0: Anti-NNC0114-0006 antibodies — Positive914
Week 0: Cross-reactivity — Negative47
Week 0: Cross-reactivity — Positive57
Week 54: Anti-NNC0114-0006 — Negative6862
Week 54: Anti-NNC0114-0006 — Positive03
Week 54: Cross-reactivity — Negative03
Week 54: Cross-reactivity — Positive00
Week 80: Anti-NNC0114-0006 antibodies — Negative6560
Week 80: Anti-NNC0114-0006 antibodies — Positive24
Week 80: Cross-reactivity — Negative12
Week 80: Cross-reactivity — Positive12
SecondaryOccurrence of Anti-liraglutide Antibodies

This outcome measure is applicable for NNC0114-0006 + Liraglutide treatment arm and Liraglutide treatment arm. Participants was assessed for anti-liraglutide antibodies. Participant who reported anti-liraglutide antibodies were further analyzed for cross-reactivity. Number of participants who measured with anti-liraglutide antibodies at week 54 and week 80 are presented.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Occurrence of Anti-liraglutide Antibodies
ParticipantsNNC0114-0006 + Liraglutide (Experimental)Liraglutide (Experimental)
Week 0: Anti-Liraglutide antibodies — Negative7775
Week 0: Anti-Liraglutide antibodies — Positive00
Week 0: Cross-reactivity to native GLP-1 — Negative00
Week 0: Cross-reactivity to native GLP-1 — Positive00
Week 54: Anti-Liraglutide antibodies — Negative6765
Week 54: Anti-Liraglutide antibodies — Positive12
Week 54: Cross-reactivity to native GLP-1 — Negative11
Week 54: Cross-reactivity to native GLP-1 — Positive01
Week 80: Anti-Liraglutide antibodies — Negative6766
Week 80: Anti-Liraglutide antibodies — Positive02
Week 80: Cross-reactivity to native GLP-1 — Negative00
Week 80: Cross-reactivity to native GLP-1 — Positive00
SecondaryChange in Insulin Dose

The total daily insulin dose was derived as the average of the doses reported on the three days prior to the visit. Change in daily total insulin dose from baseline (week 0) after 54 weeks of treatment and week 80 are presented.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Units per kilograms
Change in Insulin Dose
Units per kilogramsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-0.05 ± 0.180.02 ± 0.180.01 ± 0.230.09 ± 0.19
Change from week 0 to week 800.10 ± 0.200.05 ± 0.190.11 ± 0.220.12 ± 0.18
SecondaryChange in Number of Insulin Injections

The number of insulin injections was derived as the average of the reported number on the three days prior to the visit. The change in number of insulin injections per day (count) from baseline (week 0) after 54 weeks of treatment and week 80 are presented.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Injections per day
Change in Number of Insulin Injections
Injections per dayNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-0.3 ± 1.5-0.1 ± 1.2-0.5 ± 1.70.2 ± 1.4
Change from week 0 to week 800.2 ± 1.5-0.3 ± 1.3-0.2 ± 1.50.2 ± 1.3
SecondaryNumber of Weeks Off Bolus Insulin

The number of weeks off bolus insulin after 54 weeks of treatment and week 80 are presented.

Time frame:
(Week 0 to week 54) and (week 0 to week 80)
Reported as:
Mean · Weeks
Number of Weeks Off Bolus Insulin
WeeksNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 to week 5410 ± 185 ± 149 ± 184 ± 11
Week 0 to week 8014 ± 259 ± 2012 ± 246 ± 14
SecondaryChange in HbA1c

Change in glycosylated haemoglobin (HbA1c) is evaluated from baseline (week 0) to weeks 54 and 80.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Percentage point of HbA1c
Change in HbA1c
Percentage point of HbA1cNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54-0.7 ± 1.9-0.5 ± 1.4-0.3 ± 1.5-0.3 ± 1.9
Change from week 0 to week 80-0.1 ± 1.6-0.2 ± 1.50.5 ± 2.1-0.4 ± 1.8
SecondaryChange in Fasting Plasma Glucose

Change in fasting plasma glucose is evaluated from baseline (week 0) to weeks 54 and 80.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.5 ± 3.20.2 ± 2.4-0.3 ± 3.10.5 ± 2.4
Change from week 0 to week 801.1 ± 3.30.3 ± 2.40.2 ± 4.01.0 ± 2.4
SecondaryChange in Fasting C-peptide- Ratio to Baseline

Change in fasting C-peptide (measured in nanomole per liter \[nmol/L\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of C-peptide
Change in Fasting C-peptide- Ratio to Baseline
Ratio of C-peptideNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Ratio from week 0 to week 541.01 ± 76.80.70 ± 71.10.65 ± 102.40.66 ± 116.3
Ratio from week 0 to week 800.58 ± 112.90.53 ± 106.20.42 ± 132.50.54 ± 154.4
SecondaryChange in Fasting Glucagon- Ratio to Baseline

Change in fasting glucagon (measured in picogram per milliliter \[pg/mL\]) from baseline (week 0) to weeks 54 and 80 is presented as ratio to baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Geometric mean · Ratio of glucagon
Change in Fasting Glucagon- Ratio to Baseline
Ratio of glucagonNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Ratio from week 0 to week 541.01 ± 32.10.95 ± 32.50.96 ± 31.31.00 ± 31.4
Ratio from week 0 to week 800.89 ± 36.20.85 ± 30.70.96 ± 32.80.93 ± 37.8
Secondary7-point SMPG Profiles

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. 7-point SMPG profile values are presented for week 54 and week 80.

Time frame:
Week 54 and Week 80
Reported as:
Mean · mmol/L
7-point SMPG Profiles
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 54: Before breakfast6.8 ± 3.46.8 ± 2.76.4 ± 2.26.3 ± 1.4
Week 54: 90 minutes after start of breakfast8.9 ± 3.77.5 ± 2.47.4 ± 2.17.6 ± 2.4
Week 54: Before lunch5.5 ± 1.86.4 ± 2.36.1 ± 1.86.0 ± 1.6
Week 54: 90 minutes after start of lunch8.2 ± 2.67.5 ± 2.77.8 ± 2.47.7 ± 2.0
Week 54: Before dinner6.5 ± 1.96.5 ± 2.56.6 ± 2.26.1 ± 1.7
Week 54: 90 minutes after start of dinner8.2 ± 3.47.0 ± 2.57.2 ± 2.36.8 ± 1.9
Week 54: Bedtime7.8 ± 3.97.4 ± 2.67.5 ± 2.57.2 ± 2.1
Week 80: Before breakfast6.5 ± 1.76.4 ± 2.07.2 ± 2.76.8 ± 2.0
Week 80: 90 minutes after start of breakfast8.5 ± 2.87.2 ± 3.08.3 ± 3.77.5 ± 2.7
Week 80: Before lunch6.2 ± 2.26.2 ± 2.06.9 ± 3.36.1 ± 1.8
Week 80: 90 minutes after start of lunch7.8 ± 2.67.6 ± 2.78.5 ± 4.58.0 ± 3.0
Week 80: Before dinner6.5 ± 2.26.7 ± 2.97.6 ± 4.16.5 ± 1.6
Week 80: 90 minutes after start of dinner7.6 ± 2.57.0 ± 2.19.0 ± 5.07.6 ± 2.5
Week 80: Bedtime7.8 ± 3.06.6 ± 1.87.8 ± 4.47.4 ± 2.2
SecondaryChange in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment: Breakfast, Lunch, Dinner

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point SMPG postprandial glucose /prandial increment (breakfast, lunch and dinner) value are presented.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · mmol/L
Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment: Breakfast, Lunch, Dinner
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 54: Breakfast1.3 ± 4.00.4 ± 3.0-0.1 ± 3.8-0.6 ± 2.4
Change from week 0 to week 80: Breakfast1.9 ± 4.20.5 ± 4.0-0.1 ± 4.5-0.5 ± 4.5
Change from week 0 to week 54: Lunch0.9 ± 4.50.5 ± 3.41.5 ± 2.90.7 ± 2.7
Change from week 0 to week 80: Lunch0.0 ± 4.50.1 ± 3.01.0 ± 3.50.8 ± 4.5
Change from week 0 to week 54: Dinner0.1 ± 4.51.1 ± 4.0-0.8 ± 4.7-0.3 ± 3.1
Change from week 0 to week 80: Dinner0.5 ± 5.00.5 ± 3.4-0.4 ± 4.3-0.4 ± 3.2
SecondaryChange in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment (Average Over the Three Meals)

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in 7-point self-measured plasma glucose (SMPG) postprandial glucose /prandial increment (average over the three meals) value is presented.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · mmol/L
Change in 7- Points Self-measured Plasma Glucose (SMPG) Postprandial Glucose /Prandial Increment (Average Over the Three Meals)
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.9 ± 2.30.6 ± 2.20.2 ± 2.0-0.1 ± 2.0
Change from week 0 to week 800.8 ± 2.60.4 ± 2.20.0 ± 2.5-0.0 ± 2.9
SecondaryChange in Mean of 7-point Profiles

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime. Change from baseline (week 0) to week 54 and week 80 in mean of 7-point profiles value is presented.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · mmol/L
Change in Mean of 7-point Profiles
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Change from week 0 to week 540.5 ± 2.00.3 ± 2.4-0.1 ± 1.90.0 ± 1.2
Change from week 0 to week 800.1 ± 2.10.0 ± 2.30.7 ± 1.60.3 ± 1.7
SecondaryBefore Breakfast 7- Points Self Measured Plasma Glucose (SMPG)

Participants measured plasma glucose values using the blood glucose meter at 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Before breakfast 7-point self-measured plasma glucose (SMPG) profile values are presented at week 54 and week 80.

Time frame:
Week 54 and week 80
Reported as:
Mean · mmol/L
Before Breakfast 7- Points Self Measured Plasma Glucose (SMPG)
mmol/LNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 546.8 ± 3.46.8 ± 2.76.4 ± 2.26.3 ± 1.4
Week 806.5 ± 1.76.4 ± 2.07.2 ± 2.76.8 ± 2.0
SecondaryArea Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006)

AUCtau, NNC0114-0006 was derived as the area under the concentration-time curve using the linear trapezoidal technique based on observed values and actual measurement times between 0 and 6 weeks (after the last dose). This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Pre-dose and 1 hour post-dose during week 48 to week 54
Reported as:
Geometric mean · day*microgram per milliliter (day*ug/mL)
Area Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006)
day*microgram per milliliter (day*ug/mL)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Area Under the NNC0114-0006 Concentration-time Curve Over a Dosing Interval at Steady State (AUCtau, NNC0114-0006)3969 ± 17.94115 ± 23.1
SecondaryTerminal Half-life (t½) After Last Dose of NNC0114-0006

Terminal half life was calculated as log(2)/λz. The terminal rate constant λz was determined through linear regression with the logarithm to concentration as the response variable and actual measurement time as the explanatory variable. Valid observations from the terminal part of the curve, which is approximately linear, were used for the determination. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Pre-dose and 1 hour post-dose during week 48 to week 80
Reported as:
Geometric mean · Days
Terminal Half-life (t½) After Last Dose of NNC0114-0006
DaysNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Terminal Half-life (t½) After Last Dose of NNC0114-000622.3 ± 17.922.2 ± 16.5
SecondaryApparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006)

The apparent volume of distribution of NNC0114-0006 at steady-state was calculated as mean residence time of (MRT) of NNC0114-0006 multiplied by clearance of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Pre-dose and 1 hour post-dose during week 48 to week 80
Reported as:
Geometric mean · Milliliters per kilogram (mL/kg)
Apparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006)
Milliliters per kilogram (mL/kg)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Apparent Volume of Distribution of NNC0114-0006 at Steadystate (Vss, NNC0114-0006)83.7 ± 23.179.3 ± 17.6
SecondaryClearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006)

Clearance of NNC0114-0006 at steady state was calculated as dose/AUCtau, NNC0114-0006. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Pre-dose and 1 hour post-dose during week 48 to week 54
Reported as:
Geometric mean · (Milliliters/day)/kilogram ([mL/day]/kg)
Clearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006)
(Milliliters/day)/kilogram ([mL/day]/kg)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Clearance of NNC0114-0006 at Steady State (CLss, NNC0114-0006)3.02 ± 17.92.92 ± 23.1
SecondaryMean Residence Time of NNC0114-0006 (MRT, NNC0114-0006)

This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms. Mean residence time of NNC0114-0006 is presented.

Time frame:
Pre-dose and 1 hour post-dose during week 48 to week 80
Reported as:
Geometric mean · Days
Mean Residence Time of NNC0114-0006 (MRT, NNC0114-0006)
DaysNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Mean Residence Time of NNC0114-0006 (MRT, NNC0114-0006)27.7 ± 24.527.2 ± 22.6
SecondaryAccumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006)

Accumulation ratio of NNC114-0006 was defined as AUC48-54 weeks/AUC0-6 weeks. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Pre-dose and 1 hour post-dose during (week 0 to week 6) and (week 48 to week 54)
Reported as:
Geometric mean · Ratio of AUC
Accumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006)
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Accumulation Ratio of NNC114-0006 (RA,AUC, NNC0114-0006)1.24 ± 17.81.26 ± 17.4
SecondaryObserved NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006)

Ctrough of NNC0114-0006 was defined as concentration prior to dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Week 48 (predose)
Reported as:
Geometric mean · microgram/milliliter (ug/mL)
Observed NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006)
microgram/milliliter (ug/mL)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Observed NNC0114-0006 Concentration Prior to Dosing of NNC0114-0006 at Steady State (Ctrough, NNC0114-0006)34.7 ± 42.336.7 ± 36.8
SecondaryObserved NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006)

C1h, NNC0114-0006 was defined as concentration of NNC0114-0006 at 1 hour after dosing of NNC0114-0006 at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and NNC0114-0006 treatment arms.

Time frame:
Week 48 (1 hour post-dose)
Reported as:
Geometric mean · ug/mL
Observed NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006)
ug/mLNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)
Observed NNC0114-0006 Concentration 1 Hour After Dosing of NNC0114-0006 at Steady State (C1h, NNC0114-0006)298.6 ± 16.8282.6 ± 56.4
SecondaryLiraglutide Concentration at Steady State (C Liraglutide)

C liraglutide was defined as the liraglutide concentration at steady state. This outcome measure was applicable for NNC0114-0006 + Liraglutide and Liraglutide treatment arms.

Time frame:
Week 54 (post-dose)
Reported as:
Geometric mean · picomole per liter (pmol/L)
Liraglutide Concentration at Steady State (C Liraglutide)
picomole per liter (pmol/L)NNC0114-0006 + Liraglutide (Experimental)Liraglutide (Experimental)
Liraglutide Concentration at Steady State (C Liraglutide)16287 ± 41.715920 ± 66.0
SecondaryChange in Biomarker: Immune Phenotyping- B Cell Panel

B cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; IgMNeg refers to Immunoglobulin M negative; IgDNeg refers to Immunoglobulin D negative.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · Percentage of B cells (%)
Change in Biomarker: Immune Phenotyping- B Cell Panel
Percentage of B cells (%)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: Activated Memory B-Cells1.3 ± 0.91.4 ± 1.01.6 ± 1.11.5 ± 1.0
Week 54: Activated Memory B-Cells1.2 ± 0.81.1 ± 1.01.5 ± 1.31.3 ± 0.8
Week 80: Activated Memory B-Cells1.2 ± 0.91.1 ± 0.71.5 ± 1.11.5 ± 1.2
Week 0: Mature Naive B-Cells15.1 ± 6.714.0 ± 7.113.6 ± 6.913.3 ± 7.4
Week 54: Mature Naive B-Cells14.0 ± 6.214.3 ± 7.913.6 ± 7.613.5 ± 6.9
Week 80: Mature Naive B-Cells14.3 ± 7.314.2 ± 8.712.0 ± 5.212.8 ± 7.6
Week 0: Antibody-Secreting Cells0.6 ± 0.40.5 ± 0.50.6 ± 0.30.6 ± 0.6
Week 54: Antibody-Secreting Cells0.6 ± 0.50.4 ± 0.40.5 ± 0.30.6 ± 0.7
Week 80: Antibody-Secreting Cells0.5 ± 0.40.4 ± 0.30.4 ± 0.40.6 ± 0.5
Week 0: B-Cells Positive For Both CD19 & CD2071.9 ± 9.771.1 ± 11.172.1 ± 8.972.2 ± 8.8
Week 54: B-Cells Positive For Both CD19 & CD2071.1 ± 12.470.8 ± 12.472.1 ± 8.465.9 ± 13.6
Week 80: B-Cells Positive For Both CD19 & CD2071.0 ± 10.769.8 ± 11.272.8 ± 10.669.6 ± 13.5
Week 0: CD20Neg B-Cell0.6 ± 0.50.6 ± 0.70.6 ± 0.70.6 ± 0.5
Week 54: CD20Neg B-Cell0.6 ± 0.70.5 ± 0.90.5 ± 0.40.6 ± 0.7
Week 80: CD20Neg B-Cell0.5 ± 0.30.5 ± 0.40.6 ± 1.80.7 ± 1.0
Week 0: CD24- B-Cells29.8 ± 10.231.0 ± 11.531.5 ± 11.832.0 ± 11.1
Week 54: CD24- B-Cells30.2 ± 9.430.6 ± 10.831.3 ± 11.928.3 ± 8.9
Week 80: CD24- B-Cells30.0 ± 8.931.6 ± 10.933.4 ± 12.430.7 ± 11.8
Week 0: Class-Switched Memory B Cells5.0 ± 3.34.6 ± 2.54.8 ± 3.34.9 ± 3.0
Week 54: Class-Switched Memory B Cells5.0 ± 3.74.2 ± 2.34.6 ± 2.94.8 ± 2.9
Week 80: Class-Switched Memory B Cells4.6 ± 3.33.6 ± 2.04.6 ± 3.04.5 ± 2.5
Week 0: IgMNeg IgDNeg Switched Memory B-cells0.1 ± 0.10.1 ± 0.10.1 ± 0.10.1 ± 0.1
Week 54: IgMNeg IgDNeg Switched Memory B-cells0.1 ± 0.10.1 ± 0.10.1 ± 0.20.1 ± 0.1
Week 80: IgMNeg IgDNeg Switched Memory B-cells0.1 ± 0.10.2 ± 0.20.1 ± 0.10.1 ± 0.1
Week 0: Non-Class Switched Memory B-Cells10.2 ± 6.49.6 ± 5.89.6 ± 5.810.1 ± 6.4
Week 54: Non-Class Switched Memory B-Cells8.5 ± 4.89.0 ± 5.78.7 ± 5.88.9 ± 5.8
Week 80: Non-Class Switched Memory B-Cells8.2 ± 4.97.2 ± 4.18.0 ± 5.18.9 ± 6.2
Week 0: Total B-Cell Population72.5 ± 9.871.7 ± 11.272.7 ± 9.072.8 ± 8.6
Week 54: Total B-Cell Population71.7 ± 12.171.3 ± 11.972.6 ± 8.466.5 ± 13.3
Week 80: Total B-Cell Population71.4 ± 10.770.3 ± 11.273.5 ± 9.670.4 ± 13.0
Week 0: Transitional B-Cells11.4 ± 6.19.9 ± 6.59.5 ± 5.59.6 ± 6.6
Week 54: Transitional B-Cells10.2 ± 5.610.7 ± 7.79.5 ± 6.39.8 ± 6.4
Week 80: Transitional B-Cells10.8 ± 6.810.5 ± 8.18.1 ± 4.08.9 ± 6.1
SecondaryChange in Biomarker: Immune Phenotyping- Natural Killer (NK) Cell Panel

NK cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table ADCC refer to Antibody-dependent cellular cytotoxicity; CD refer to Cluster of Differentiation.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · Percentage of NK cells (%)
Change in Biomarker: Immune Phenotyping- Natural Killer (NK) Cell Panel
Percentage of NK cells (%)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: ADCC-Competent NK39.5 ± 17.136.3 ± 14.936.0 ± 16.634.7 ± 14.6
Week 54: ADCC-Competent NK37.1 ± 16.132.5 ± 14.133.9 ± 14.031.5 ± 14.0
Week 80: ADCC-Competent NK37.1 ± 16.033.2 ± 13.731.9 ± 15.134.1 ± 16.3
Week 0: CD16+ Highly Functional NK Cells0.8 ± 0.80.8 ± 0.70.7 ± 0.60.7 ± 0.6
Week 54: CD16+ Highly Functional NK Cells0.7 ± 0.70.7 ± 0.80.7 ± 0.70.6 ± 0.5
Week 80: CD16+ Highly Functional NK Cells0.7 ± 0.80.6 ± 0.50.6 ± 0.60.8 ± 0.7
Week 0: CD56- Cells34.5 ± 15.936.8 ± 15.538.0 ± 17.138.0 ± 13.6
Week 54: CD56- Cells34.8 ± 12.836.6 ± 12.938.1 ± 14.341.1 ± 15.7
Week 80: CD56- Cells36.2 ± 14.337.6 ± 13.737.1 ± 11.737.6 ± 12.7
Week 0: CD56High NK Pool4.9 ± 3.35.1 ± 3.54.5 ± 2.94.9 ± 3.7
Week 54: CD56High NK Pool4.9 ± 3.15.3 ± 3.44.2 ± 2.94.4 ± 3.0
Week 80: CD56High NK Pool4.5 ± 2.95.1 ± 3.14.3 ± 2.85.4 ± 4.0
Week 0: CD57+ MatNK Effectors22.6 ± 12.520.4 ± 10.321.0 ± 11.819.0 ± 10.1
Week 54: CD57+ MatNK Effectors21.0 ± 12.518.0 ± 10.118.9 ± 10.616.6 ± 9.4
Week 80: CD57+ MatNK Effectors20.0 ± 11.218.3 ± 9.017.5 ± 11.117.3 ± 9.6
Week 0: Functional NK Cells; Efficient At ADCC14.5 ± 7.813.3 ± 8.513.1 ± 9.712.1 ± 6.4
Week 54: Functional NK Cells; Efficient At ADCC13.2 ± 8.511.1 ± 7.212.1 ± 7.111.0 ± 7.2
Week 80: Functional NK Cells; Efficient At ADCC13.3 ± 7.411.3 ± 7.110.9 ± 7.212.6 ± 9.4
Week 0: Highly Cytolytic Subset Of NK Cells18.8 ± 10.420.9 ± 10.320.6 ± 11.021.4 ± 9.4
Week 54: Highly Cytolytic Subset Of NK Cells22.2 ± 10.724.5 ± 11.022.8 ± 11.522.1 ± 11.0
Week 80: Highly Cytolytic Subset Of NK Cells21.1 ± 9.723.0 ± 9.125.5 ± 11.421.9 ± 9.9
Week 0: Mature CD16+ Highly Functional NK Cells0.7 ± 0.70.7 ± 0.60.6 ± 0.60.7 ± 0.6
Week 54: Mature CD16+ Highly Functional NK Cells0.6 ± 0.60.6 ± 0.80.6 ± 0.70.6 ± 0.5
Week 80: Mature CD16+ Highly Functional NK Cells0.6 ± 0.70.6 ± 0.50.5 ± 0.60.7 ± 0.7
Week 0: Mature CD16+ Terminally Differentiated1.3 ± 1.31.1 ± 1.21.1 ± 1.11.3 ± 1.1
Week 54: Mature CD16+ Terminally Differentiated0.9 ± 0.70.8 ± 0.71.0 ± 0.91.1 ± 0.9
Week 80: Mature CD16+ Terminally Differentiated1.1 ± 1.11.0 ± 1.00.8 ± 0.91.3 ± 1.0
Week 0: Mature CD16- Terminally Differentiate NK0.3 ± 0.20.3 ± 0.20.4 ± 0.40.4 ± 0.3
Week 54: Mature CD16- Terminally Differentiate NK0.3 ± 0.20.3 ± 0.20.3 ± 0.30.4 ± 0.2
Week 80: Mature CD16- Terminally Differentiate NK0.3 ± 0.20.3 ± 0.30.4 ± 0.31.0 ± 4.2
Week 0: Mature Cytolytic NK Cells2.3 ± 1.42.2 ± 1.12.4 ± 1.72.3 ± 1.3
Week 54: Mature Cytolytic NK Cells2.4 ± 1.42.7 ± 1.52.5 ± 1.62.4 ± 1.7
Week 80: Mature Cytolytic NK Cells2.3 ± 1.22.9 ± 3.72.6 ± 2.32.5 ± 1.5
Week 0: Mature Rapid Cytokine-Producing NK Cell3.6 ± 2.53.8 ± 2.83.3 ± 2.23.6 ± 2.8
Week 54: Mature Rapid Cytokine-Producing NK Cell3.6 ± 2.43.9 ± 2.43.0 ± 2.03.3 ± 2.4
Week 80: Mature Rapid Cytokine-Producing NK Cell3.2 ± 2.03.7 ± 2.43.0 ± 1.93.9 ± 3.0
Week 0: Rapid Cytokine-Producing NK Cell Subset4.1 ± 2.74.4 ± 3.13.8 ± 2.64.1 ± 3.2
Week 54: Rapid Cytokine-Producing NK Cell Subset4.2 ± 2.74.5 ± 2.83.5 ± 2.33.8 ± 2.6
Week 80: Rapid Cytokine-Producing NK Cell Subset3.8 ± 2.34.4 ± 2.73.7 ± 2.34.6 ± 3.4
Week 0: Senescent CD16+ CD56- NK cells1.3 ± 1.81.2 ± 1.91.0 ± 1.11.2 ± 1.2
Week 54: Senescent CD16+ CD56- NK cells1.0 ± 1.11.2 ± 1.50.9 ± 0.91.1 ± 1.1
Week 80: Senescent CD16+ CD56- NK cells1.1 ± 1.41.4 ± 1.50.9 ± 0.91.2 ± 1.0
Week 0: Senescent CD16+CD56hi NK0.1 ± 0.20.1 ± 0.10.1 ± 0.10.1 ± 0.1
Week 54: Week 0: Senescent CD16+CD56hi NK0.1 ± 0.10.0 ± 0.10.1 ± 0.10.0 ± 0.1
Week 80: Week 0: Senescent CD16+CD56hi NK0.1 ± 0.10.0 ± 0.00.1 ± 0.10.1 ± 0.1
Week 0: Senescent CD16- CD56- NK cells1.3 ± 1.01.5 ± 1.61.3 ± 1.01.5 ± 1.1
Week 54: Senescent CD16- CD56- NK cells1.5 ± 1.21.8 ± 1.31.6 ± 1.32.0 ± 2.9
Week 80: Senescent CD16- CD56- NK cells1.9 ± 2.02.4 ± 3.71.9 ± 1.32.2 ± 3.3
Week 0: Senescent Cytolytic NK Cells8.7 ± 6.69.9 ± 7.29.8 ± 7.29.9 ± 6.0
Week 54: Senescent Cytolytic NK Cells9.9 ± 6.311.3 ± 7.610.9 ± 7.99.6 ± 6.7
Week 80: Senescent Cytolytic NK Cells9.4 ± 6.111.1 ± 7.111.5 ± 7.99.8 ± 7.3
Week 0: Senescent Rapid Cytokine-Producing NK0.1 ± 0.30.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 54: Senescent Rapid Cytokine-Producing NK0.0 ± 0.00.0 ± 0.00.0 ± 0.10.0 ± 0.0
Week 80: Senescent Rapid Cytokine-Producing NK0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.1
Week 0: Total CD16+ CD56- NK6.7 ± 3.87.4 ± 5.16.4 ± 3.57.3 ± 3.8
Week 54: Total CD16+ CD56- NK5.9 ± 2.66.2 ± 3.86.0 ± 3.16.8 ± 3.5
Week 80: Total CD16+ CD56- NK6.8 ± 5.86.6 ± 4.16.2 ± 3.07.3 ± 3.5
Week 0: Total CD16- CD56- NK27.6 ± 15.429.2 ± 13.231.4 ± 16.730.5 ± 13.0
Week 54: Week 0: Total CD16- CD56- NK28.6 ± 12.230.1 ± 11.931.9 ± 13.334.0 ± 14.1
Week 80: Week 0: Total CD16- CD56- NK29.2 ± 12.730.7 ± 13.230.7 ± 10.230.0 ± 12.2
Week 0: Total Mature NK Cells; Highly Cytolytic58.6 ± 13.457.4 ± 15.156.8 ± 16.656.3 ± 13.7
Week 54: Total Mature NK Cells; Highly Cytolytic59.6 ± 13.457.3 ± 12.956.9 ± 13.853.7 ± 15.0
Week 80: Total Mature NK Cells; Highly Cytolytic58.5 ± 13.956.5 ± 13.457.7 ± 12.156.2 ± 11.6
SecondaryChange in Biomarker: Immune Phenotyping- T Cell Panel

T cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CD refer to Cluster of Differentiation; TEMRA refers to terminally differentiated effector memory cells re-expressing CD45RA; CCR refers to C-C chemokine receptor; TREG refers to Regulatory T cells.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · Percentage of T cells (%)
Change in Biomarker: Immune Phenotyping- T Cell Panel
Percentage of T cells (%)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: Activated CD4 TEMRA10.1 ± 7.19.7 ± 5.410.8 ± 6.89.7 ± 6.5
Week 54: Activated CD4 TEMRA10.3 ± 5.98.7 ± 5.39.7 ± 5.49.3 ± 6.0
Week 80: Activated CD4 TEMRA9.1 ± 5.58.1 ± 5.58.1 ± 4.98.7 ± 5.0
Week 0: Activated CD8 TEMRA0.9 ± 1.20.8 ± 1.40.6 ± 0.61.0 ± 1.9
Week 54: Activated CD8 TEMRA0.9 ± 1.50.6 ± 0.70.6 ± 0.60.7 ± 1.0
Week 80: Activated CD8 TEMRA0.7 ± 0.90.6 ± 0.70.6 ± 0.61.1 ± 2.3
Week 0: Activated Central Memory CD46.3 ± 3.36.7 ± 3.17.1 ± 3.86.1 ± 3.2
Week 54: Activated Central Memory CD46.3 ± 3.16.1 ± 3.16.3 ± 2.96.2 ± 3.1
Week 80: Activated Central Memory CD46.5 ± 3.06.0 ± 2.66.0 ± 2.66.5 ± 2.8
Week 0: Activated Central Memory CD81.1 ± 1.21.7 ± 1.81.6 ± 1.71.1 ± 1.0
Week 54: Activated Central Memory CD81.4 ± 1.61.6 ± 1.81.5 ± 1.43.1 ± 13.3
Week 80: Activated Central Memory CD82.2 ± 6.51.4 ± 1.51.6 ± 2.31.9 ± 4.5
Week 0: Activated Effector Memory CD410.3 ± 5.810.9 ± 5.611.3 ± 6.49.4 ± 4.8
Week 54: Activated Effector Memory CD410.1 ± 5.49.6 ± 5.210.0 ± 4.99.2 ± 4.8
Week 80: Activated Effector Memory CD410.2 ± 6.68.9 ± 4.39.5 ± 4.89.1 ± 4.3
Week 0: Activated Effector Memory CD81.9 ± 3.61.7 ± 2.91.2 ± 1.40.9 ± 1.2
Week 54: Activated Effector Memory CD82.0 ± 3.71.6 ± 2.41.2 ± 1.21.1 ± 1.4
Week 80: Activated Effector Memory CD81.9 ± 3.41.5 ± 2.81.4 ± 2.01.1 ± 1.4
Week 0: Activated Mature Naive CD4 T-Cells4.0 ± 2.04.0 ± 1.94.7 ± 2.43.9 ± 1.8
Week 54: Activated Mature Naive CD4 T-Cells3.9 ± 2.13.8 ± 1.84.5 ± 2.33.7 ± 1.4
Week 80: Activated Mature Naive CD4 T-Cells4.0 ± 2.43.8 ± 1.44.0 ± 1.93.9 ± 1.7
Week 0: Activated Mature Naive CD8 T-Cells3.4 ± 3.72.8 ± 2.33.3 ± 3.53.5 ± 3.7
Week 54: Activated Mature Naive CD8 T-Cells3.0 ± 3.32.6 ± 3.02.6 ± 2.73.1 ± 3.6
Week 80: Activated Mature Naive CD8 T-Cells2.7 ± 2.12.6 ± 2.52.5 ± 2.73.1 ± 3.2
Week 0: CCR5+ CD4 TEMRA17.7 ± 12.216.4 ± 8.116.9 ± 11.118.9 ± 12.8
Week 54: CCR5+ CD4 TEMRA18.4 ± 12.217.7 ± 10.318.8 ± 13.521.0 ± 17.3
Week 80: CCR5+ CD4 TEMRA18.3 ± 11.019.5 ± 13.618.6 ± 11.921.4 ± 15.1
Week 0: CCR5+ CD4 Treg TEMRA3.7 ± 10.61.7 ± 1.82.7 ± 4.73.9 ± 8.6
Week 54: CCR5+ CD4 Treg TEMRA4.2 ± 9.14.2 ± 10.44.6 ± 10.54.6 ± 9.3
Week 80: CCR5+ CD4 Treg TEMRA2.8 ± 4.64.4 ± 10.43.2 ± 5.74.4 ± 9.3
Week 0: CCR5+ CD8 EM35.3 ± 14.535.5 ± 13.838.2 ± 14.137.7 ± 15.8
Week 54: CCR5+ CD8 EM37.9 ± 14.136.4 ± 13.538.0 ± 14.438.8 ± 15.5
Week 80: CCR5+ CD8 EM38.8 ± 15.334.7 ± 12.437.5 ± 14.140.0 ± 16.3
Week 0: CCR5+ CD8 TEMRA22.8 ± 10.222.9 ± 10.925.9 ± 12.924.3 ± 12.6
Week 54: CCR5+ CD8 TEMRA25.9 ± 10.725.0 ± 9.726.3 ± 12.125.4 ± 11.6
Week 80: CCR5+ CD8 TEMRA25.9 ± 11.324.4 ± 11.326.8 ± 13.426.9 ± 13.1
Week 0: CCR5+ Central Memory CD4 Cells4.1 ± 2.44.3 ± 2.34.5 ± 2.94.5 ± 3.2
Week 54: CCR5+ Central Memory CD4 Cells4.5 ± 2.54.1 ± 2.04.1 ± 2.84.9 ± 3.4
Week 80: CCR5+ Central Memory CD4 Cells4.9 ± 2.54.9 ± 3.75.1 ± 3.45.7 ± 4.7
Week 0: CCR5+ Central Memory CD8 Cells15.0 ± 10.614.4 ± 9.016.9 ± 10.316.7 ± 11.1
Week 54: CCR5+ Central Memory CD8 Cells16.8 ± 9.014.2 ± 9.715.8 ± 9.718.5 ± 15.6
Week 80: CCR5+ Central Memory CD8 Cells16.8 ± 8.915.5 ± 8.915.8 ± 9.219.3 ± 13.5
Week 0: CCR5+ Central Memory Regulatory T-Cells1.9 ± 1.71.8 ± 1.41.8 ± 1.91.5 ± 1.1
Week 54: CCR5+ Central Memory Regulatory T-Cells2.0 ± 1.71.5 ± 1.31.7 ± 1.81.7 ± 1.3
Week 80: CCR5+ Central Memory Regulatory T-Cells2.1 ± 1.91.8 ± 1.71.9 ± 1.92.2 ± 2.4
Week 0: CCR5+ Effector Memory CD415.5 ± 7.914.5 ± 7.615.5 ± 8.315.3 ± 7.4
Week 54: CCR5+ Effector Memory CD416.2 ± 7.715.7 ± 7.614.9 ± 7.516.9 ± 9.6
Week 80: CCR5+ Effector Memory CD417.5 ± 7.516.8 ± 9.216.4 ± 8.018.4 ± 10.9
Week 0: CCR5+ Effector Memory Regulatory T-Cells4.7 ± 3.55.1 ± 3.34.5 ± 3.94.1 ± 2.3
Week 54: CCR5+ Effector Memory Regulatory T-Cells4.8 ± 3.04.6 ± 3.14.4 ± 3.34.5 ± 2.5
Week 80: CCR5+ Effector Memory Regulatory T-Cells5.2 ± 3.65.2 ± 4.05.4 ± 5.35.2 ± 3.2
Week 0: CCR5+ Naive CD4 T-Cells1.9 ± 1.52.0 ± 1.32.1 ± 1.92.0 ± 1.8
Week 54: CCR5+ Naive CD4 T-Cells2.0 ± 1.52.1 ± 2.12.1 ± 1.92.3 ± 2.2
Week 80: CCR5+ Naive CD4 T-Cells2.3 ± 1.62.9 ± 3.92.8 ± 3.03.5 ± 5.1
Week 0: CCR5+ Naive CD8 T-Cells3.7 ± 2.33.5 ± 1.94.1 ± 2.84.2 ± 3.2
Week 54: CCR5+ Naive CD8 T-Cells3.4 ± 1.73.5 ± 2.43.5 ± 2.14.1 ± 2.9
Week 80: CCR5+ Naive CD8 T-Cells3.8 ± 1.84.0 ± 4.34.3 ± 3.14.9 ± 4.7
Week 0: CCR5+ Naive Regulatory T-Cells6.1 ± 6.55.0 ± 3.66.5 ± 8.36.5 ± 8.8
Week 54: CCR5+ Naive Regulatory T-Cells6.7 ± 10.16.3 ± 7.34.8 ± 5.55.3 ± 5.2
Week 80: CCR5+ Naive Regulatory T-Cells5.8 ± 4.96.5 ± 8.45.7 ± 6.57.1 ± 8.0
Week 0: CD4 TEMRA3.7 ± 4.92.6 ± 1.73.1 ± 2.52.7 ± 2.3
Week 54: CD4 TEMRA3.8 ± 5.72.9 ± 2.33.3 ± 2.83.1 ± 3.2
Week 80: CD4 TEMRA4.4 ± 5.83.2 ± 2.33.6 ± 3.23.5 ± 2.6
Week 0: CD8 Central Memory2.0 ± 1.82.0 ± 2.11.8 ± 1.51.9 ± 1.3
Week 54: CD8 Central Memory1.8 ± 1.22.1 ± 2.31.7 ± 1.42.1 ± 1.6
Week 80: CD8 Central Memory1.8 ± 1.61.9 ± 2.01.8 ± 1.52.2 ± 2.0
Week 0: CD8 Effector Memory14.3 ± 7.914.7 ± 7.613.4 ± 7.715.7 ± 6.9
Week 54: CD8 Effector Memory15.1 ± 7.614.8 ± 7.811.3 ± 6.616.4 ± 7.4
Week 80: CD8 Effector Memory15.1 ± 8.016.5 ± 9.013.9 ± 7.617.4 ± 7.5
Week 0: CD8 TEMRA31.6 ± 12.830.9 ± 13.929.0 ± 12.832.3 ± 13.8
Week 54: CD8 TEMRA29.8 ± 12.331.0 ± 13.930.3 ± 12.930.4 ± 13.3
Week 80: CD8 TEMRA31.9 ± 14.333.5 ± 13.130.4 ± 13.033.4 ± 14.6
Week 0: Conventional Central Memory CD4 T-Cells20.0 ± 9.922.1 ± 8.020.3 ± 8.121.6 ± 8.0
Week 54: Conventional Central Memory CD4 T-Cells20.4 ± 8.122.2 ± 9.319.9 ± 7.821.1 ± 8.0
Week 80: Conventional Central Memory CD4 T-Cells19.4 ± 8.421.7 ± 7.819.9 ± 8.221.1 ± 8.7
Week 0: Conventional Effector Memory CD4 T-Cells19.2 ± 10.722.8 ± 10.319.5 ± 9.520.7 ± 9.2
Week 54: Conventional Effector Memory CD4 T-Cells20.3 ± 9.622.9 ± 11.020.5 ± 10.721.3 ± 9.7
Week 80: Conventional Effector Memory CD4 T-Cells20.0 ± 9.824.4 ± 11.320.9 ± 11.723.2 ± 10.0
Week 0: Naive CD4 T-Cells57.0 ± 14.752.4 ± 14.457.0 ± 12.654.9 ± 13.2
Week 54: Naive CD4 T-Cells55.4 ± 11.951.8 ± 15.056.3 ± 13.954.5 ± 12.5
Week 80: Naive CD4 T-Cells56.1 ± 11.950.6 ± 16.255.6 ± 15.152.1 ± 14.5
Week 0: Naive CD8 T-Cells52.0 ± 15.952.5 ± 19.155.8 ± 17.050.1 ± 17.4
Week 54: Naive CD8 T-Cells53.2 ± 14.952.1 ± 18.154.7 ± 15.451.1 ± 17.4
Week 80: Naive CD8 T-Cells51.1 ± 16.048.1 ± 19.253.9 ± 17.446.9 ± 17.6
Week 0: Senescent CD4 Central Memory Cells2.3 ± 1.92.2 ± 1.52.4 ± 2.62.3 ± 2.7
Week 54: Senescent CD4 Central Memory Cells1.9 ± 1.52.1 ± 1.72.2 ± 1.92.4 ± 2.5
Week 80: Senescent CD4 Central Memory Cells2.3 ± 1.82.3 ± 1.62.1 ± 1.62.6 ± 2.4
Week 0: Senescent CD4 Effector Memory Cells6.9 ± 5.56.3 ± 5.66.9 ± 5.46.7 ± 6.5
Week 54: Senescent CD4 Effector Memory Cells5.9 ± 5.86.7 ± 6.06.6 ± 4.97.5 ± 9.0
Week 80: Senescent CD4 Effector Memory Cells6.9 ± 5.97.0 ± 5.26.4 ± 4.77.6 ± 7.4
Week 0: Senescent CD8 Central Memory Cells12.1 ± 10.111.5 ± 9.112.9 ± 9.712.4 ± 12.7
Week 54: Senescent CD8 Central Memory Cells11.7 ± 9.510.4 ± 9.212.0 ± 10.212.2 ± 14.5
Week 80: Senescent CD8 Central Memory Cells12.7 ± 9.012.7 ± 9.911.3 ± 9.812.2 ± 11.9
Week 0: Senescent CD8 Effector Memory Cells27.3 ± 14.827.2 ± 15.527.7 ± 13.629.1 ± 17.4
Week 54: Senescent CD8 Effector Memory Cells25.2 ± 13.125.1 ± 14.326.1 ± 12.825.8 ± 14.7
Week 80: Senescent CD8 Effector Memory Cells27.5 ± 14.528.6 ± 15.726.5 ± 14.126.6 ± 15.5
Week 0: Senescent Naive CD4 T-Cells2.6 ± 2.72.9 ± 3.32.6 ± 2.32.5 ± 2.3
Week 54: Senescent Naive CD4 T-Cells2.5 ± 2.53.0 ± 3.82.8 ± 3.02.7 ± 2.4
Week 80: Senescent Naive CD4 T-Cells3.1 ± 3.33.3 ± 3.83.1 ± 3.73.9 ± 5.3
Week 0: Senescent Naive CD8 T-Cells3.9 ± 3.43.6 ± 3.53.5 ± 3.14.2 ± 4.4
Week 54: Senescent Naive CD8 T-Cells3.5 ± 2.93.8 ± 4.53.7 ± 4.34.2 ± 3.6
Week 80: Senescent Naive CD8 T-Cells4.4 ± 4.34.3 ± 4.73.8 ± 3.64.5 ± 4.1
Week 0: Senescent Naive TREG6.9 ± 7.95.5 ± 3.77.1 ± 8.57.3 ± 9.3
Week 54: Senescent Naive TREG7.2 ± 10.96.8 ± 7.85.0 ± 5.55.6 ± 5.2
Week 80: Senescent Naive TREG6.3 ± 5.77.0 ± 8.96.0 ± 7.27.4 ± 8.2
Week 0: Senescent TEMRA CD423.3 ± 19.821.7 ± 18.421.9 ± 21.722.0 ± 20.1
Week 54: Senescent TEMRA CD420.0 ± 17.122.8 ± 18.323.1 ± 22.223.5 ± 21.7
Week 80: Senescent TEMRA CD421.0 ± 19.524.2 ± 18.121.7 ± 21.525.4 ± 21.6
Week 0: Senescent TEMRA CD842.8 ± 20.240.3 ± 21.037.7 ± 19.442.0 ± 23.0
Week 54: Senescent TEMRA CD839.2 ± 19.840.7 ± 21.338.3 ± 18.440.4 ± 22.9
Week 80: Senescent TEMRA CD842.7 ± 21.444.8 ± 20.938.7 ± 20.443.5 ± 23.1
Week 0: Senescent TEMRA TREG3.6 ± 19.71.8 ± 1.92.8 ± 4.64.0 ± 8.6
Week 54: Senescent TEMRA TREG3.9 ± 9.04.2 ± 10.44.6 ± 10.54.6 ± 9.1
Week 80: Senescent TEMRA TREG2.6 ± 4.54.4 ± 10.43.2 ± 5.74.4 ± 9.3
Week 0: Senescent TREG CM0.1 ± 0.10.1 ± 0.10.1 ± 0.20.2 ± 0.2
Week 54: Senescent TREG CM0.1 ± 0.10.1 ± 0.10.1 ± 0.20.2 ± 0.2
Week 80: Senescent TREG CM0.2 ± 0.20.2 ± 0.10.1 ± 0.20.3 ± 0.5
Week 0: Senescent TREG EM0.4 ± 0.40.4 ± 0.30.4 ± 0.50.4 ± 0.4
Week 54: Senescent TREG EM0.4 ± 0.40.3 ± 0.30.3 ± 0.30.5 ± 0.5
Week 80: Senescent TREG EM0.5 ± 0.70.5 ± 0.90.5 ± 0.70.5 ± 0.7
Week 0: Total Naive TREG46.8 ± 18.142.4 ± 14.150.3 ± 14.247.7 ± 17.6
Week 54: Total Naive TREG43.7 ± 15.644.3 ± 15.849.4 ± 15.445.1 ± 13.7
Week 80: Total Naive TREG46.8 ± 15.744.1 ± 18.348.7 ± 17.043.4 ± 15.2
Week 0: Total TREG3.9 ± 1.93.8 ± 1.54.1 ± 1.63.5 ± 1.3
Week 54: Total TREG3.8 ± 1.53.5 ± 1.54.0 ± 1.53.5 ± 1.2
Week 80: Total TREG3.7 ± 1.53.5 ± 1.33.4 ± 1.23.4 ± 1.2
Week 0: Total TREG CM14.8 ± 9.215.8 ± 8.114.4 ± 7.914.2 ± 7.9
Week 54: Total TREG CM15.5 ± 9.015.6 ± 9.513.8 ± 7.815.0 ± 6.7
Week 80: Total TREG CM15.3 ± 8.715.0 ± 8.213.8 ± 7.415.9 ± 8.2
Week 0: Total TREG EM30.8 ± 14.636.4 ± 11.228.8 ± 12.230.7 ± 15.2
Week 54: Total TREG EM32.4 ± 14.632.6 ± 12.528.3 ± 12.931.9 ± 13.6
Week 80: Total TREG EM30.7 ± 13.733.5 ± 13.930.2 ± 15.032.9 ± 13.3
Week 0: Total TREG TEMRA7.6 ± 11.55.5 ± 3.56.7 ± 5.77.5 ± 9.0
Week 54: Total TREG TEMRA8.5 ± 11.47.7 ± 10.58.6 ± 10.48.2 ± 10.3
Week 80: Total TREG TEMRA7.3 ± 8.17.4 ± 10.37.5 ± 6.87.8 ± 9.3
Week 0: Total Viable CD4 T-Cells54.7 ± 10.753.2 ± 8.754.6 ± 11.354.6 ± 11.5
Week 54: Total Viable CD4 T-Cells54.3 ± 11.352.1 ± 12.254.6 ± 12.752.7 ± 12.7
Week 80: Total Viable CD4 T-Cells51.9 ± 13.350.3 ± 13.853.1 ± 12.652.2 ± 13.5
Week 0: Total Viable CD8 T-Cells26.1 ± 8.128.2 ± 8.725.8 ± 7.626.6 ± 8.3
Week 54: Total Viable CD8 T-Cells25.0 ± 7.926.7 ± 9.424.6 ± 7.924.0 ± 9.8
Week 80: Total Viable CD8 T-Cells24.2 ± 8.925.4 ± 9.523.5 ± 8.923.9 ± 9.7
Week 0: Total Viable T-Cells55.6 ± 7.155.2 ± 8.155.3 ± 8.055.0 ± 7.2
Week 54: Total Viable T-Cells53.6 ± 7.055.9 ± 6.757.4 ± 7.755.5 ± 8.7
Week 80: Total Viable T-Cells52.7 ± 8.655.3 ± 7.956.2 ± 8.055.8 ± 7.9
SecondaryChange in Biomarker: Immune Phenotyping- T Follicular Helper (TfH) Cell Panel

TfH cell panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table CTFH refer to Circulating T follicular helper; ICOS refers to inducible T-cell co-stimulator; PD refers to Programmed cell death protein; CCR refers to C-C chemokine receptor; CXCR refers to C-X-C chemokine receptor; CD refer to Cluster of Differentiation; CM refers to central memory; EM refers to effector memory, TIGIT refers to T cell immunoreceptor with Ig and ITIM domains.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · Percentage of TfH cells (%)
Change in Biomarker: Immune Phenotyping- T Follicular Helper (TfH) Cell Panel
Percentage of TfH cells (%)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: Activated cTfh17 Cells0.8 ± 1.21.0 ± 2.20.8 ± 1.60.6 ± 0.9
Week 54: Activated cTfh17 Cells0.6 ± 1.20.4 ± 0.80.7 ± 1.20.9 ± 2.0
Week 80: Activated cTfh17 Cells0.8 ± 2.01.1 ± 2.90.6 ± 0.80.9 ± 1.4
Week 0: Activated cTfh2 Cells0.6 ± 0.60.6 ± 0.60.6 ± 0.50.6 ± 0.6
Week 54: Activated cTfh2 Cells0.4 ± 0.40.4 ± 0.40.7 ± 1.20.6 ± 0.6
Week 80: Activated cTfh2 Cells0.6 ± 0.60.5 ± 0.30.5 ± 0.50.6 ± 0.6
Week 0:Activated PD1+ICOS+ cTfh11.3 ± 1.71.9 ± 7.71.1 ± 1.21.0 ± 1.1
Week 54: Activated PD1+ICOS+ cTfh10.7 ± 0.61.0 ± 1.21.2 ± 2.51.2 ± 1.4
Week 80: Activated PD1+ICOS+ cTfh10.7 ± 0.60.9 ± 1.01.0 ± 2.11.1 ± 2.5
Week 0: CCR7+ cTfh1 Cells96.9 ± 2.597.1 ± 3.594.7 ± 13.497.2 ± 2.2
Week 54: CCR7+ cTfh1 Cells97.1 ± 2.595.8 ± 13.197.1 ± 4.297.3 ± 2.3
Week 80: CCR7+ cTfh1 Cells97.0 ± 3.096.8 ± 3.097.4 ± 2.197.0 ± 2.3
Week 0: CCR7+ cTfh17 Cells97.4 ± 11.797.4 ± 11.997.4 ± 12.597.3 ± 11.8
Week 54: CCR7+ cTfh17 Cells98.1 ± 2.993.9 ± 22.396.9 ± 12.995.3 ± 18.3
Week 80: CCR7+ cTfh17 Cells98.7 ± 1.597.3 ± 5.996.8 ± 13.498.7 ± 1.4
Week 0: CCR7+ cTfh2 Cells98.1 ± 1.698.2 ± 1.498.2 ± 1.598.3 ± 1.4
Week 54: CCR7+ cTfh2 Cells98.1 ± 1.998.5 ± 1.298.3 ± 1.198.1 ± 1.6
Week 80: CCR7+ cTfh2 Cells98.3 ± 1.598.3 ± 1.898.4 ± 1.198.3 ± 1.0
Week 0: CXCR4+ cTfh1 Cells59.4 ± 27.658.0 ± 25.954.9 ± 27.855.6 ± 29.2
Week 54: CXCR4+ cTfh1 Cells64.5 ± 28.764.5 ± 28.864.4 ± 29.369.4 ± 25.0
Week 80: CXCR4+ cTfh1 Cells70.8 ± 24.566.4 ± 27.463.5 ± 30.366.8 ± 25.2
Week 0: CXCR4+ cTfh17 Cells50.9 ± 30.445.8 ± 27.843.7 ± 29.345.1 ± 31.4
Week 54: CXCR4+ cTfh17 Cells56.1 ± 31.154.0 ± 29.353.1 ± 31.456.4 ± 29.6
Week 80: CXCR4+ cTfh17 Cells60.0 ± 27.457.2 ± 30.354.6 ± 31.457.6 ± 28.5
Week 0: CXCR4+ Ctfh2 Cells58.8 ± 26.856.3 ± 25.254.0 ± 26.354.5 ± 28.8
Week 54: CXCR4+ Ctfh2 Cells63.3 ± 28.265.2 ± 27.363.7 ± 28.567.7 ± 25.3
Week 80: CXCR4+ Ctfh2 Cells69.3 ± 23.965.8 ± 27.162.7 ± 29.566.7 ± 24.7
Week 0: Circulating TFH-Cells (cTfh)5.5 ± 3.75.4 ± 3.46.2 ± 3.36.1 ± 3.7
Week 54: Circulating TFH-Cells (cTfh)5.7 ± 3.35.6 ± 3.96.2 ± 4.06.2 ± 4.4
Week 80: Circulating TFH-Cells (cTfh)5.8 ± 3.35.9 ± 4.16.1 ± 4.25.8 ± 3.8
Week 0: ICOS+ CD4 CM0.5 ± 0.50.5 ± 0.50.4 ± 0.30.5 ± 0.4
Week 54: ICOS+ CD4 CM0.3 ± 0.20.3 ± 0.20.4 ± 0.20.4 ± 0.3
Week 80: ICOS+ CD4 CM0.3 ± 0.30.3 ± 0.20.3 ± 0.20.3 ± 0.2
Week 0: ICOS+ CD4 EM0.2 ± 0.20.3 ± 0.60.2 ± 0.20.2 ± 0.2
Week 54: ICOS+ CD4 EM0.2 ± 0.10.2 ± 0.10.2 ± 0.10.2 ± 0.1
Week 80: ICOS+ CD4 EM0.2 ± 0.10.2 ± 0.10.2 ± 0.50.2 ± 0.1
Week 0: ICOS+ CD4 TEMRA0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 54: ICOS+ CD4 TEMRA0.0 ± 0.00.0 ± 0.00.0 ± 0.00.0 ± 0.0
Week 80: ICOS+ CD4 TEMRA0.0 ± 0.00.0 ± 0.00.0 ± 0.10.0 ± 0.0
Week 0: ICOS+ NAIVE CD4 T-Cells0.1 ± 0.10.1 ± 0.10.1 ± 0.10.1 ± 0.1
Week 54: ICOS+ NAIVE CD4 T-Cells0.0 ± 0.10.0 ± 0.00.0 ± 0.10.1 ± 0.1
Week 80: ICOS+ NAIVE CD4 T-Cells0.0 ± 0.10.0 ± 0.00.0 ± 0.10.0 ± 0.0
Week 0: ICOS+ NAIVE TREG2.3 ± 1.82.7 ± 3.41.9 ± 2.12.5 ± 2.8
Week 54: ICOS+ NAIVE TREG2.1 ± 2.02.0 ± 2.41.9 ± 2.52.4 ± 2.5
Week 80: ICOS+ NAIVE TREG2.2 ± 2.22.1 ± 2.41.9 ± 2.32.7 ± 2.7
Week 0: ICOS+ TREG CM10.9 ± 5.311.3 ± 5.810.4 ± 5.411.0 ± 5.9
Week 54: ICOS+ TREG CM10.0 ± 5.29.2 ± 4.49.7 ± 4.710.6 ± 5.1
Week 80: ICOS+ TREG CM10.1 ± 4.99.0 ± 4.38.8 ± 5.210.5 ± 4.4
Week 0: ICOS+ TREG EM12.8 ± 6.413.3 ± 6.813.0 ± 6.212.8 ± 6.5
Week 54: ICOS+ TREG EM11.9 ± 5.811.6 ± 5.912.8 ± 6.112.7 ± 5.9
Week 80: ICOS+ TREG EM12.0 ± 5.511.3 ± 5.410.5 ± 5.312.0 ± 5.8
Week 0: ICOS+ TREG TEMRA10.2 ± 10.613.0 ± 18.410.5 ± 11.49.3 ± 8.6
Week 54: ICOS+ TREG TEMRA8.8 ± 10.59.7 ± 10.711.0 ± 12.612.8 ± 15.1
Week 80: ICOS+ TREG TEMRA9.9 ± 9.89.6 ± 10.18.2 ± 9.211.0 ± 10.5
Week 0: PD1+ CD4 Central Memory6.2 ± 4.06.7 ± 4.97.2 ± 5.36.6 ± 4.3
Week 54: PD1+ CD4 Central Memory6.4 ± 4.76.8 ± 5.47.2 ± 5.46.7 ± 3.9
Week 80: PD1+ CD4 Central Memory6.7 ± 5.57.5 ± 5.96.8 ± 4.87.2 ± 5.3
Week 0: PD1+ CD4 Effector Memory4.0 ± 3.24.2 ± 2.34.0 ± 2.84.1 ± 2.6
Week 54: PD1+ CD4 Effector Memory3.7 ± 3.03.9 ± 2.23.6 ± 2.34.0 ± 2.5
Week 80: PD1+ CD4 Effector Memory3.9 ± 2.74.3 ± 2.33.6 ± 2.24.3 ± 2.4
Week 0: PD1+ Naive CD43.8 ± 6.13.0 ± 4.74.2 ± 6.83.2 ± 4.4
Week 54: PD1+ Naive CD44.2 ± 6.22.9 ± 4.04.4 ± 6.83.5 ± 4.6
Week 80: PD1+ Naive CD45.0 ± 8.43.3 ± 4.64.2 ± 6.63.8 ± 6.2
Week 0: PD1+ Naive TREG8.4 ± 6.88.7 ± 7.58.4 ± 7.98.5 ± 8.0
Week 54: PD1+ Naive TREG9.8 ± 7.99.4 ± 9.59.1 ± 8.59.4 ± 8.2
Week 80: PD1+ Naive TREG11.0 ± 9.810.1 ± 9.19.3 ± 8.210.7 ± 9.2
Week 0: PD1+ TEMRA TREG22.5 ± 19.023.5 ± 17.519.8 ± 15.019.5 ± 13.5
Week 54: PD1+ TEMRA TREG20.5 ± 13.719.7 ± 16.218.6 ± 14.021.4 ± 13.9
Week 80: PD1+ TEMRA TREG22.5 ± 15.025.7 ± 19.522.4 ± 16.622.7 ± 13.0
Week 0: PD1+ TREG CM16.8 ± 10.017.5 ± 11.517.3 ± 11.017.2 ± 10.2
Week 54: PD1+ TREG CM16.5 ± 10.516.7 ± 10.916.8 ± 11.418.0 ± 10.6
Week 80: PD1+ TREG CM18.1 ± 13.018.7 ± 11.216.6 ± 11.018.8 ± 11.6
Week 0: PD1+ TREG EM20.1 ± 9.921.1 ± 11.421.6 ± 10.920.9 ± 10.0
Week 54: PD1+ TREG EM19.3 ± 10.519.8 ± 10.321.1 ± 11.621.6 ± 10.7
Week 80: PD1+ TREG EM20.6 ± 12.221.1 ± 10.519.4 ± 10.621.9 ± 10.0
Week 0: PD1+ICOSNeg cTfh130.0 ± 14.828.8 ± 15.332.4 ± 16.529.7 ± 13.2
Week 54: PD1+ICOSNeg cTfh130.5 ± 16.229.1 ± 13.934.2 ± 19.031.0 ± 13.5
Week 80: PD1+ICOSNeg cTfh132.4 ± 18.130.7 ± 16.031.3 ± 14.032.8 ± 13.6
Week 0: PD1+ICOSNeg cTfh1721.8 ± 16.322.5 ± 16.323.7 ± 17.122.3 ± 15.7
Week 54: PD1+ICOSNeg cTfh1721.8 ± 17.421.1 ± 16.926.2 ± 19.721.7 ± 15.5
Week 80: PD1+ICOSNeg cTfh1726.8 ± 19.224.7 ± 16.023.6 ± 15.824.3 ± 15.5
Week 0: PD1+ICOSNeg cTfh219.1 ± 12.018.4 ± 12.620.8 ± 14.318.5 ± 11.2
Week 54: PD1+ICOSNeg cTfh218.4 ± 13.318.1 ± 13.120.2 ± 14.418.8 ± 11.7
Week 80: PD1+ICOSNeg cTfh220.2 ± 16.619.6 ± 13.918.9 ± 11.720.2 ± 13.2
Week 0: PD1- ICOS- cTfh168.4 ± 15.169.0 ± 16.364.6 ± 17.968.9 ± 13.5
Week 54: PD1- ICOS- cTfh168.6 ± 16.468.0 ± 16.564.1 ± 19.767.5 ± 14.1
Week 80: PD1- ICOS- cTfh166.7 ± 18.268.1 ± 16.167.4 ± 14.465.9 ± 14.0
Week 0: PD1- ICOS- cTfh1775.6 ± 18.874.7 ± 18.273.4 ± 19.375.3 ± 18.1
Week 54: PD1- ICOS- cTfh1777.4 ± 17.972.9 ± 23.770.9 ± 21.573.5 ± 20.9
Week 80: PD1- ICOS- cTfh1772.1 ± 20.174.0 ± 16.273.6 ± 18.774.6 ± 15.8
Week 0: PD1- ICOS- cTfh280.1 ± 12.280.8 ± 12.878.3 ± 14.280.7 ± 11.5
Week 54: PD1- ICOS- cTfh281.0 ± 13.381.3 ± 13.378.8 ± 14.380.3 ± 11.9
Week 80: PD1- ICOS- cTfh279.1 ± 16.979.8 ± 13.980.4 ± 11.979.0 ± 13.4
Week 0: Potentially Anergic TEMRA CD40.7 ± 2.50.2 ± 0.30.4 ± 1.00.3 ± 0.7
Week 54: Potentially Anergic TEMRA CD40.8 ± 3.00.2 ± 0.30.5 ± 1.30.3 ± 0.5
Week 80: Potentially Anergic TEMRA CD40.8 ± 2.90.2 ± 0.30.5 ± 1.40.3 ± 0.7
Week 0: Regulatory T-Follicular Subset0.2 ± 0.20.2 ± 0.20.2 ± 0.20.2 ± 0.2
Week 54: Regulatory T-Follicular Subset0.2 ± 0.20.2 ± 0.20.2 ± 0.20.3 ± 0.2
Week 80: Regulatory T-Follicular Subset0.2 ± 0.20.2 ± 0.30.2 ± 0.30.3 ± 0.3
Week 0: TH17-Like Circulating T-Follicular cells0.5 ± 0.50.4 ± 0.40.5 ± 0.50.5 ± 0.5
Week 54: TH17-Like Circulating T-Follicular cells0.4 ± 0.40.4 ± 0.40.4 ± 0.50.4 ± 0.4
Week 80: TH17-Like Circulating T-Follicular cells0.4 ± 0.50.4 ± 0.50.3 ± 0.30.4 ± 0.5
Week 0: TH2-Like Circulating T-Follicular Cells3.6 ± 2.23.6 ± 2.04.0 ± 2.04.1 ± 2.3
Week 54: TH2-Like Circulating T-Follicular Cells3.9 ± 2.03.6 ± 2.24.0 ± 2.33.9 ± 2.5
Week 80: TH2-Like Circulating T-Follicular Cells3.8 ± 2.03.7 ± 2.13.9 ± 2.23.8 ± 2.1
Week 0: TIGIT+ cTfh153.0 ± 11.648.5 ± 13.953.4 ± 12.451.6 ± 13.1
Week 54: TIGIT+ cTfh151.1 ± 13.147.6 ± 13.952.2 ± 14.150.2 ± 14.1
Week 80: TIGIT+ cTfh151.4 ± 11.148.1 ± 14.449.6 ± 10.452.7 ± 12.2
Week 0: TIGIT+ cTfh1740.5 ± 16.236.2 ± 13.139.3 ± 14.538.7 ± 14.9
Week 54: TIGIT+ cTfh1737.0 ± 13.531.4 ± 16.540.7 ± 14.735.8 ± 15.6
Week 80: TIGIT+ cTfh1739.4 ± 14.535.9 ± 13.935.3 ± 12.736.8 ± 13.8
Week 0: TIGIT+ cTfh244.4 ± 9.540.9 ± 9.844.8 ± 7.443.4 ± 9.8
Week 54: TIGIT+ cTfh241.1 ± 11.037.9 ± 10.942.0 ± 9.641.0 ± 11.6
Week 80: TIGIT+ cTfh240.7 ± 10.438.4 ± 9.540.5 ± 8.441.9 ± 9.9
Week 0: TOTAL ICOS+ TREG8.6 ± 4.49.6 ± 5.58.0 ± 3.88.9 ± 4.5
Week 54: TOTAL ICOS+ TREG8.3 ± 4.87.5 ± 3.57.6 ± 3.88.6 ± 3.6
Week 80: TOTAL ICOS+ TREG8.3 ± 4.47.4 ± 3.66.6 ± 3.38.6 ± 3.6
Week 0: Th1-Like Circulating T-Follicular Cells1.3 ± 1.41.3 ± 1.21.6 ± 1.21.5 ± 1.3
Week 54: Th1-Like Circulating T-Follicular Cells1.4 ± 1.21.6 ± 1.71.8 ± 1.51.8 ± 1.9
Week 80: Th1-Like Circulating T-Follicular Cells1.5 ± 1.41.8 ± 1.91.9 ± 2.01.6 ± 1.5
Week 0: Total PD1+ TREG14.5 ± 7.915.1 ± 8.214.7 ± 8.914.4 ± 7.4
Week 54: Total PD1+ TREG14.8 ± 9.114.3 ± 8.514.5 ± 9.115.0 ± 7.6
Week 80: Total PD1+ TREG16.0 ± 10.615.9 ± 8.314.2 ± 9.016.1 ± 8.9
SecondaryChange in Biomarker: Immune Phenotyping- Myeloid Cell Panel

Myeloid panel is evaluated by Immune phenotyping of peripheral blood mononuclear cells (PBMC) at baseline (week 0), week 54 and week 80. In below table HLA refers to Human Leukocyte Antigen; MDSC refers to myeloid-derived suppressor cell; DC refers to Dendritic cells; MYDC refers to Myeloid Dendritic Cells; IMMYE_MDSC refers to Immature myeloid cells \& a subset of myeloid suppressor cells within the CD14-HLA class II- myeloid cell population.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · Percentage of Myeloid cells (%)
Change in Biomarker: Immune Phenotyping- Myeloid Cell Panel
Percentage of Myeloid cells (%)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0: CD14+ HLA low Myeloid Cells1.1 ± 1.51.0 ± 1.30.9 ± 1.21.0 ± 1.4
Week 54: CD14+ HLA low Myeloid Cells1.1 ± 2.30.7 ± 0.90.7 ± 1.10.6 ± 1.1
Week 80: CD14+ HLA low Myeloid Cells1.0 ± 2.20.6 ± 0.70.9 ± 1.20.8 ± 1.1
Week 0: CD14+ MDSC68.2 ± 20.869.1 ± 22.373.5 ± 19.470.3 ± 18.6
Week 54: CD14+ MDSC64.0 ± 23.467.0 ± 23.269.3 ± 21.465.9 ± 20.2
Week 80: CD14+ MDSC65.7 ± 22.362.7 ± 20.864.1 ± 23.363.9 ± 23.2
Week 0: CD14-HLA II- Myeloid Cells Total Myeloid80.4 ± 11.082.2 ± 10.480.8 ± 12.181.8 ± 11.0
Week 54: CD14-HLA II- Myeloid Cells Total Myeloid80.9 ± 11.780.0 ± 12.080.8 ± 12.783.5 ± 10.5
Week 80: CD14-HLA II- Myeloid Cells Total Myeloid79.0 ± 12.981.0 ± 10.880.9 ± 9.781.3 ± 8.4
Week 0: CD16+ Dendritic Cells12.5 ± 8.411.3 ± 7.512.9 ± 10.611.5 ± 7.5
Week 54: CD16+ Dendritic Cells10.2 ± 8.110.3 ± 7.511.2 ± 9.712.0 ± 9.7
Week 80: CD16+ Dendritic Cells11.7 ± 10.69.4 ± 6.19.2 ± 7.112.1 ± 8.0
Week 0: IMMYE_MDSC0.3 ± 0.20.2 ± 0.20.2 ± 0.20.2 ± 0.4
Week 54: IMMYE_MDSC0.2 ± 0.30.2 ± 0.30.2 ± 0.30.1 ± 0.2
Week 80: IMMYE_MDSC0.2 ± 0.30.1 ± 0.20.2 ± 0.20.2 ± 0.2
Week 0: Intermediate Monocyte Subset8.6 ± 8.49.0 ± 7.88.3 ± 8.87.7 ± 7.3
Week 54: Intermediate Monocyte Subset6.5 ± 4.87.3 ± 6.76.3 ± 7.15.8 ± 5.4
Week 80: Intermediate Monocyte Subset6.0 ± 5.16.6 ± 6.55.7 ± 5.45.8 ± 4.5
Week 0: Non-Classical Monocytes1.5 ± 1.31.3 ± 0.81.2 ± 0.81.3 ± 1.0
Week 54: Non-Classical Monocytes1.2 ± 1.11.3 ± 0.81.1 ± 0.81.2 ± 0.9
Week 80: Non-Classical Monocytes1.2 ± 0.71.2 ± 0.71.0 ± 0.61.3 ± 0.9
Week 0: Total Classical Monocytes87.2 ± 9.386.7 ± 8.187.6 ± 9.188.0 ± 8.0
Week 54: Total Classical Monocytes87.8 ± 7.988.1 ± 7.688.0 ± 8.889.3 ± 6.8
Week 80: Total Classical Monocytes89.3 ± 6.088.5 ± 7.188.6 ± 7.089.7 ± 5.4
Week 0: Total Monocytes in Myeloid Cells14.2 ± 8.912.6 ± 7.814.1 ± 9.513.4 ± 8.7
Week 54: Total Monocytes in Myeloid Cells13.8 ± 9.314.9 ± 9.814.3 ± 10.612.2 ± 8.3
Week 80: Total Monocytes in Myeloid Cells15.5 ± 10.313.8 ± 9.113.6 ± 7.613.5 ± 6.3
Week 0: Total Myeloid DC3.8 ± 2.13.6 ± 2.33.8 ± 2.83.4 ± 2.0
Week 54: Total Myeloid DC3.7 ± 2.33.9 ± 2.43.8 ± 2.43.2 ± 2.1
Week 80: Total Myeloid DC4.1 ± 2.34.1 ± 2.54.1 ± 3.03.9 ± 2.1
Week 0: Total MYDC30.4 ± 9.131.4 ± 10.232.7 ± 9.231.0 ± 9.6
Week 54: Total MYDC30.4 ± 11.331.3 ± 8.531.7 ± 11.927.2 ± 9.2
Week 80: Total MYDC28.7 ± 10.730.5 ± 7.931.6 ± 12.031.9 ± 10.2
Week 0: Total Percent Of Myeloid Cells94.6 ± 3.894.7 ± 5.494.6 ± 3.494.6 ± 4.1
Week 54: Total Percent Of Myeloid Cells95.1 ± 3.695.9 ± 4.095.0 ± 3.895.6 ± 3.7
Week 80: Total Percent Of Myeloid Cells94.8 ± 5.495.6 ± 4.094.6 ± 4.494.1 ± 5.1
Week 0: Total Plasmacytoid Dendritic Cells (PDC)14.3 ± 5.412.5 ± 6.612.0 ± 6.312.9 ± 7.5
Week 54: Total Plasmacytoid Dendritic Cells (PDC)14.4 ± 6.713.5 ± 5.912.0 ± 6.111.8 ± 6.5
Week 80: Total Plasmacytoid Dendritic Cells (PDC)13.5 ± 6.612.8 ± 6.711.6 ± 6.312.5 ± 6.7
SecondaryAutoantibodies Against Glutamic Acid Decarboxylase (GAD)

Participants were analyzed for autoantibodies against Glutamic acid decarboxylase (GAD) and were categorized as negative and positive.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Autoantibodies Against Glutamic Acid Decarboxylase (GAD)
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 — Negative3153
Week 0 — Positive74767174
Week 54 — Negative5443
Week 54 — Positive62616463
Week 80 — Negative4251
Week 80 — Positive61626361
SecondaryAutoantibodies Against Zinc-transporter 8 (ZnT8)

Participants were analyzed for autoantibodies against Zinc-transporter 8 (ZnT8) and were categorized as negative and positive.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Autoantibodies Against Zinc-transporter 8 (ZnT8)
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 — Negative29303036
Week 0 — Positive48474641
Week 54 — Negative26282733
Week 54 — Positive42374133
Week 80 — Negative23303133
Week 80 — Positive42343729
SecondaryAutoantibodies Against Islet Antigen-2 (IA2)

Participants were analyzed for autoantibodies against Islet antigen-2 (IA2) and were categorized as negative and positive.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Autoantibodies Against Islet Antigen-2 (IA2)
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 — Negative38373145
Week 0 — Positive39404532
Week 54 — Negative35332838
Week 54 — Positive33324028
Week 80 — Negative32382935
Week 80 — Positive33263927
SecondaryAutoantibodies Against Insulin Autoantibodies (IAA)

Participants were analyzed for autoantibodies against Insulin autoantibodies (IAA) and were categorized as negative and positive.

Time frame:
Week 0, week 54 and week 80
Reported as:
Count of participants · Participants
Autoantibodies Against Insulin Autoantibodies (IAA)
ParticipantsNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0 — Negative35282636
Week 0 — Positive42484940
Week 54 — Negative30282211
Week 54 — Positive38374655
Week 80 — Negative18241315
Week 80 — Positive48405547
SecondaryChange in Biomarker: Total Interleukin-21 (IL-21)

IL-21 is evaluated at baseline (week 0), week 54 and week 80.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · picogram per milliliter
Change in Biomarker: Total Interleukin-21 (IL-21)
picogram per milliliterNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 028.8 ± 10.231.1 ± 10.830.9 ± 10.730.2 ± 10.2
Week 543993.5 ± 2145.44368.2 ± 2374.925.0 ± 0.034.1 ± 68.1
Week 80540.9 ± 495.3674.1 ± 648.128.0 ± 8.230.7 ± 17.2
SecondaryChange in Biomarker: Serum Vitamin D (1,25 Dehydroxy-calciferol)

Serum vitamin D is evaluated at baseline (week 0), week 54 and week 80.

Time frame:
Week 0, week 54 and week 80
Reported as:
Mean · picomole per liter
Change in Biomarker: Serum Vitamin D (1,25 Dehydroxy-calciferol)
picomole per literNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 0123 ± 30122 ± 39122 ± 29120 ± 33
Week 54117 ± 31125 ± 36113 ± 30119 ± 32
Week 80119 ± 41124 ± 49121 ± 38115 ± 33
SecondaryChange in Short Form 36 Health Survey (SF-36)

SF-36v2™ questionnaire measured the HRQoL on 8 domains (Bodily Pain, General Health, Mental Health, Physical Functioning, Role Emotion, Physical Health, Social Functioning and Vitality) on individual scale ranges. The scores 0-100 (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. Change from baseline (week 0) to week 54 and week 80 in SF-36 score is presented.The MCS measure is derived from domain scales of vitality, social functioning, role emotional and mental health. The PCS measure is derived from domain scales of physical functioning, role-physical, bodily pain, and general health. A norm-based score of 50 corresponds to the mean score and 10 corresponds to the standard deviation of the 2009 U.S. general population. A positive change score indicate an improvement since baseline.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Score on a scale
Change in Short Form 36 Health Survey (SF-36)
Score on a scaleNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 54: Bodily pain-0.8 ± 8.5-2.2 ± 7.60.1 ± 5.20.6 ± 9.1
Week 80: Bodily Pain0.8 ± 7.8-1.4 ± 7.0-0.5 ± 6.40.8 ± 10.2
Week 54: General Health Perception-1.1 ± 7.1-0.3 ± 8.4-1.6 ± 7.3-1.0 ± 7.1
Week 80: General Health Perception-0.9 ± 7.20.6 ± 9.0-1.7 ± 7.9-1.8 ± 8.6
Week 54: Mental Component Sum0.5 ± 9.40.6 ± 9.3-2.1 ± 9.0-1.3 ± 7.6
Week 80: Mental Component Sum1.7 ± 9.8-0.4 ± 8.9-2.4 ± 9.6-0.7 ± 8.7
week 54: Mental Health0.7 ± 8.40.6 ± 7.9-1.5 ± 8.6-1.3 ± 6.9
Week 80: Mental Health1.5 ± 8.6-0.2 ± 8.0-1.5 ± 9.0-0.7 ± 7.6
Week 54: Physical Component Sum-0.4 ± 4.2-0.4 ± 5.3-0.1 ± 3.80.3 ± 5.7
Week 80: Physical Component Sum-0.1 ± 3.90.5 ± 5.40.0 ± 4.30.0 ± 6.9
Week 54: Physical Functioning0.6 ± 2.50.9 ± 4.40.0 ± 2.60.3 ± 5.8
Week 80: Physical Functioning0.5 ± 2.91.1 ± 4.6-0.1 ± 2.40.1 ± 6.4
Week 54:Lim Emotion Prob0.3 ± 10.70.5 ± 8.9-1.4 ± 9.0-0.1 ± 8.5
Week 80: Lim Emotion Prob1.2 ± 10.8-0.1 ± 9.8-2.2 ± 9.40.0 ± 8.3
Week 54: Lim. Phy Health0.3 ± 5.80.7 ± 6.9-0.6 ± 5.7-0.2 ± 6.9
Week 80: Lim. Phy Health0.8 ± 6.40.9 ± 7.0-0.2 ± 5.20.0 ± 7.3
Week 54: Social Functioning0.8 ± 10.30.1 ± 10.0-1.4 ± 7.40.0 ± 8.5
Week 80: Social Functioning2.3 ± 9.91.0 ± 8.3-1.2 ± 7.3-0.4 ± 8.4
Week 54: Vitality-0.5 ± 8.20.5 ± 7.9-2.2 ± 5.9-2.3 ± 6.9
Week 80: Vitality0.5 ± 7.9-1.4 ± 6.9-2.2 ± 7.1-0.7 ± 6.9
SecondaryChange in Experience of Treatment Benefits and Barriers (ETBB)

Treatment Benefits and Barriers (ETBB) questionnaire measured diabetes-specific health beliefs on 2 categories: Total Score for Perceived Barriers and Perceived Benefits. The measurement of perceived benefits of, and barriers to, treatment was achieved by creating a pool 28 statements each with a 7-point scale ranging from strongly agree (6) to strongly disagree (0). ETBB benefits score was calculated using the responses from questions 1, 4, 7, 8, 10, and 12 and ETBB barriers score was calculated using the responses from questions 2, 3, 5, 6, 9, and 11. Both was calculated as the sum of responses divided by number of responses received multiplied by the maximum number of responses. Based on the responses used the maximum responses available was 6. The higher score indicates more perceived benefits or more perceived barrier.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Median · score on a scale
Change in Experience of Treatment Benefits and Barriers (ETBB)
score on a scaleNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 54: Total Score for Perceived Barriers-1.2 ± 8.3-1.8 ± 7.7-0.2 ± 8.2-0.3 ± 6.3
Week 80: Total Score for Perceived Barriers-2.0 ± 7.8-2.0 ± 7.5-0.1 ± 6.70.1 ± 8.3
Week 54: Total Score for Perceived Benefits0.6 ± 5.61.1 ± 4.20.2 ± 5.7-0.5 ± 6.3
Week 80: Total Score for Perceived Benefits0.1 ± 5.81.1 ± 4.81.3 ± 6.2-0.4 ± 5.1
SecondaryChange in Diabetes Treatment Satisfaction Questionnaire (DTSQ)

Change from baseline (week 0) in DTSQ is evaluated at week 54 and 80. The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher score indicates a higher level of glycaemia/treatment satisfaction.

Time frame:
(Week 0, week 54) and (week 0, week 80)
Reported as:
Mean · Score on a scale
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Score on a scaleNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Week 54: Perceived frequency of hyperglycaemia0.6 ± 1.90.0 ± 1.50.0 ± 1.90.5 ± 1.7
Week 80: Perceived frequency of hyperglycaemia0.9 ± 1.80.5 ± 1.80.6 ± 2.00.7 ± 1.9
Week 54: Perceived frequency of hypoglycaemia-0.7 ± 2.1-0.6 ± 1.6-0.4 ± 2.1-0.2 ± 1.5
Week 80: Perceived frequency of hypoglycaemia-0.9 ± 1.8-0.3 ± 1.7-0.4 ± 1.8-0.1 ± 1.5
Week 54: Treatment satisfaction1.5 ± 4.80.9 ± 5.21.3 ± 4.80.2 ± 5.5
Week 80: Treatment satisfaction1.3 ± 6.11.2 ± 5.70.0 ± 5.10.2 ± 6.2
SecondaryArea Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline

Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a mixed meal tolerance test (MMTT) stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as Nano moles\*hour per liter (nmol\*h/L).

Time frame:
0 - 4 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of AUC
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 80 Relative to Baseline0.566 ± 71.30.598 ± 70.20.373 ± 115.80.571 ± 100.9
SecondaryAUC0-2h of C-peptide at Week 80 Relative to Baseline

Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. AUC of C-peptide was measured as 'nmol\*h/L'.

Time frame:
0-2 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of AUC
AUC0-2h of C-peptide at Week 80 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-2h of C-peptide at Week 80 Relative to Baseline0.590 ± 74.50.619 ± 71.20.370 ± 111.50.540 ± 120.6
SecondaryCmax of C-peptide at Week 80 Relative to Baseline

Maximum observed concentration (Cmax) of a MMTT stimulated C-peptide at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as nanomoles per liter (nmol/L).

Time frame:
0-4 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of Cmax
Cmax of C-peptide at Week 80 Relative to Baseline
Ratio of CmaxNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Cmax of C-peptide at Week 80 Relative to Baseline0.580 ± 74.80.592 ± 76.80.389 ± 109.00.568 ± 97.7
SecondaryAUC0-4h of Glucose at Week 80 Relative to Baseline

Area under the concentration-time curve, from 0 to 4 hours (AUC0-4h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as Milli moles\*hour per liter (mmol\*h/L).

Time frame:
0 - 4 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of AUC
AUC0-4h of Glucose at Week 80 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-4h of Glucose at Week 80 Relative to Baseline1.129 ± 33.31.115 ± 32.61.136 ± 39.01.221 ± 26.6
SecondaryAUC0-2h of Glucose at Week 80 Relative to Baseline

Area under the concentration-time curve, from 0 to 2 hours (AUC0-2h) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. AUC of glucose was measured as 'mmol\*h/L'.

Time frame:
0-2 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of AUC
AUC0-2h of Glucose at Week 80 Relative to Baseline
Ratio of AUCNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
AUC0-2h of Glucose at Week 80 Relative to Baseline1.119 ± 28.61.086 ± 28.11.070 ± 35.51.166 ± 21.7
SecondaryCmax of Glucose at Week 80 Relative to Baseline

Maximum observed concentration (Cmax) of a MMTT stimulated glucose at week 80 is presented as ratio to baseline. Cmax of C-peptide was measured as 'mmol/L'.

Time frame:
0-4 hours post-dose on week 0 and week 80
Reported as:
Geometric mean · Ratio of Cmax
Cmax of Glucose at Week 80 Relative to Baseline
Ratio of CmaxNNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)
Cmax of Glucose at Week 80 Relative to Baseline1.114 ± 25.61.074 ± 28.71.104 ± 31.01.155 ± 21.5

Adverse events

Collected over Weeks 0-80. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NNC0114-0006 + Liraglutide0/77 (0%)7/77 (9.1%)57/77 (74%)
NNC0114-00060/77 (0%)5/77 (6.5%)55/77 (71.4%)
Liraglutide1/76 (1.3%)9/76 (11.8%)62/76 (81.6%)
Placebo0/77 (0%)11/77 (14.3%)54/77 (70.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventNNC0114-0006 + LiraglutideNNC0114-0006LiraglutidePlacebo
Diabetic metabolic decompensationMetabolism and nutrition disorders2/770/771/762/77
Brain oedemaNervous system disorders0/770/771/760/77
Clavicle fractureInjury, poisoning and procedural complications0/770/771/760/77
ConcussionInjury, poisoning and procedural complications0/770/771/761/77
Diabetic ketoacidosisMetabolism and nutrition disorders0/770/771/761/77
Genital herpes simplexInfections and infestations0/770/771/760/77
Hypoglycaemic comaNervous system disorders0/770/771/760/77
KetosisMetabolism and nutrition disorders0/770/771/760/77
Nasal septum deviationRespiratory, thoracic and mediastinal disorders0/770/771/760/77
Oral herpesInfections and infestations0/770/771/760/77
Most frequent other events
Showing 10 of 34
Most frequent other events
EventNNC0114-0006 + LiraglutideNNC0114-0006LiraglutidePlacebo
NauseaGastrointestinal disorders19/776/7742/769/77
NasopharyngitisInfections and infestations20/7727/7725/7625/77
VomitingGastrointestinal disorders14/770/7717/764/77
DiarrhoeaGastrointestinal disorders15/779/7713/769/77
Decreased appetiteMetabolism and nutrition disorders14/772/7711/761/77
Oropharyngeal painRespiratory, thoracic and mediastinal disorders10/7713/775/769/77
InfluenzaInfections and infestations6/7712/772/762/77
HeadacheNervous system disorders11/7710/7710/7611/77
Abdominal painGastrointestinal disorders9/770/774/767/77
Upper respiratory tract infectionInfections and infestations8/775/774/767/77

Baseline characteristics

The Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(years)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)Total
Mean28.0 ± 7.528.6 ± 7.928.0 ± 7.129.0 ± 7.028.4 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)Total
Female21322528106
Male56455149201
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)Total
Hispanic or Latino432110
Not Hispanic or Latino73747476297
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)NNC0114-0006 + Liraglutide (Experimental)NNC0114-0006 (Experimental)Liraglutide (Experimental)Placebo (Placebo)Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American02114
White73707376292
More than one race00000
Unknown or Not Reported442010
09

Study locations

108 sites
  • Novo Nordisk Investigational Site
    La Jolla, California 92037, United States
  • Novo Nordisk Investigational Site
    Northridge, California 91325, United States
  • Novo Nordisk Investigational Site
    Aurora, Colorado 80045, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33136, United States
  • Novo Nordisk Investigational Site
    Orlando, Florida 32804, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Teaneck, New Jersey 07666, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27517, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37203, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77079, United States
  • Novo Nordisk Investigational Site
    Mesquite, Texas 75149, United States
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5020, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1130, Austria
  • Novo Nordisk Investigational Site
    Brussel, 1090, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2E1, Canada
  • Novo Nordisk Investigational Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Novo Nordisk Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Novo Nordisk Investigational Site
    Kingston, Ontario K7L 2V7, Canada
  • Novo Nordisk Investigational Site
    Toronto, Ontario M4G 3E8, Canada
  • Novo Nordisk Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • Novo Nordisk Investigational Site
    Montreal, Quebec H4A 3T2, Canada
  • Novo Nordisk Investigational Site
    PQ, Quebec G1L 3L5, Canada
  • Novo Nordisk Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novo Nordisk Investigational Site
    Aarhus N, 8200, Denmark
  • Novo Nordisk Investigational Site
    Esbjerg, 6700, Denmark
  • Novo Nordisk Investigational Site
    Hellerup, 2900, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00290, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90220, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33520, Finland
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 15, Ireland
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 4, Ireland
  • Novo Nordisk Investigational Site
    Galway, H91 YR71, Ireland
  • Novo Nordisk Investigational Site
    Holon, 58100, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Petah Tikva, 49202, Israel
  • Novo Nordisk Investigational Site
    Rehovot, 76100, Israel
  • Novo Nordisk Investigational Site
    Bergamo, 24127, Italy
  • Novo Nordisk Investigational Site
    Catanzaro, 88100, Italy
  • Novo Nordisk Investigational Site
    Milano, 20132, Italy
  • Novo Nordisk Investigational Site
    Siena, 53100, Italy
  • Novo Nordisk Investigational Site
    Oslo, 0586, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4011, Norway
  • Novo Nordisk Investigational Site
    Gdansk, 80-214, Poland
  • Novo Nordisk Investigational Site
    Gdansk, 80-546, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 04-736, Poland
  • Novo Nordisk Investigational Site
    Zabrze, 41-800, Poland
  • Novo Nordisk Investigational Site
    Almada, 2805-267, Portugal
  • Novo Nordisk Investigational Site
    Amadora, 2720-276, Portugal
  • Novo Nordisk Investigational Site
    Braga, 4710-243, Portugal
  • Novo Nordisk Investigational Site
    Matosinhos, 4464-513, Portugal
  • Novo Nordisk Investigational Site
    Porto, 4200-319, Portugal
  • Novo Nordisk Investigational Site
    Viana do Castelo, 4901-858, Portugal
  • Novo Nordisk Investigational Site
    Arkhangelsk, 163001, Russian Federation
  • Novo Nordisk Investigational Site
    Chelyabinsk, 454048, Russian Federation
  • Novo Nordisk Investigational Site
    Dzerzhinskiy, 140091, Russian Federation
  • Novo Nordisk Investigational Site
    Kazan, 420012, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 123423, Russian Federation
  • Novo Nordisk Investigational Site
    Moscow, 125315, Russian Federation
  • Novo Nordisk Investigational Site
    Novosibirsk, 630091, Russian Federation
  • Novo Nordisk Investigational Site
    Penza, 440026, Russian Federation
  • Novo Nordisk Investigational Site
    Saint-Petersburg, 199226, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410031, Russian Federation
  • Novo Nordisk Investigational Site
    Saratov, 410053, Russian Federation
  • Novo Nordisk Investigational Site
    Syktyvkar, 167981, Russian Federation
  • Novo Nordisk Investigational Site
    Ulianovsk, 432063, Russian Federation
  • Novo Nordisk Investigational Site
    Yoshkar-Ola, 424004, Russian Federation
  • Novo Nordisk Investigational Site
    Belgrade, 11000, Serbia
  • Novo Nordisk Investigational Site
    Kragujevac, 34000, Serbia
  • Novo Nordisk Investigational Site
    Barcelona, 08035, Spain
  • Novo Nordisk Investigational Site
    Girona, 17007, Spain
  • Novo Nordisk Investigational Site
    Málaga, 29010, Spain
  • Novo Nordisk Investigational Site
    Palma de Mallorca, 07198, Spain
  • Novo Nordisk Investigational Site
    Sabadell, 08208, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41003, Spain
  • Novo Nordisk Investigational Site
    Sevilla, 41009, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
  • Novo Nordisk Investigational Site
    Göteborg, 413 45, Sweden
  • Novo Nordisk Investigational Site
    Karlstad, 651 85, Sweden
  • Novo Nordisk Investigational Site
    Lund, 221 85, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 141 86, Sweden
  • Novo Nordisk Investigational Site
    Kyiv, 02091, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 02232, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 03049, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 04053, Ukraine
  • Novo Nordisk Investigational Site
    Kyiv, 04114, Ukraine
  • Novo Nordisk Investigational Site
    Vinnytsia, 21010, Ukraine
  • Novo Nordisk Investigational Site
    Zhytomyr, 10002, Ukraine
  • Novo Nordisk Investigational Site
    Belfast, BT12 6BA, United Kingdom
  • Novo Nordisk Investigational Site
    Blackburn, BB2 3HH, United Kingdom
  • Novo Nordisk Investigational Site
    Bristol, BS10 5NB, United Kingdom
  • Novo Nordisk Investigational Site
    Cardiff, CF14 4XW, United Kingdom
  • Novo Nordisk Investigational Site
    Chester, CH2 1UL, United Kingdom

Showing the first 100 of 108 sites across 18 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • von Herrath M, Bain SC, Bode B, Clausen JO, Coppieters K, Gaysina L, Gumprecht J, Hansen TK, Mathieu C, Morales C, Mosenzon O, Segel S, Tsoukas G, Pieber TR; Anti-IL-21-liraglutide Study Group investigators and contributors. Anti-interleukin-21 antibody and liraglutide for the preservation of beta-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2021 Apr;9(4):212-224. doi: 10.1016/S2213-8587(21)00019-X. Epub 2021 Mar 1. PubMed 33662334 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Aug 2018, 33 months.

Results were first posted in Jan 2021, 2 years 4 months after primary completion. A results delay was requested in Aug 2019.

Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's 33 months is above that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 13, 2015
StartActual
Nov 10, 2015
Primary completionActual
Aug 31, 2018
CompletionActual
Feb 27, 2019
Results delay requested
Aug 16, 2019
Results first posted
Jan 11, 2021
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02443155
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 13, 2015
Start date
Nov 10, 2015
Primary completion
Aug 31, 2018
Completion
Feb 27, 2019
Results posted
Jan 11, 2021
Last update
Apr 9, 2021

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: NNC0114-0006 · Liraglutide

Start the discussion